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Abstract 
 
This thesis describes the expansion and improvement of the iterative in situ click 
chemistry OBOC peptide library screening technology.  Previous work provided a proof-of-concept 
demonstration that this technique was advantageous for the production of protein-catalyzed 
capture (PCC) agents that could be used as drop-in replacements for antibodies in a variety of 
applications.  Chapter 2 describes the technology development that was undertaken to optimize 
this screening process and make it readily available for a wide variety of targets.  This optimization 
is what has allowed for the explosive growth of the PCC agent project over the past few years. 
These technology improvements were applied to the discovery of PCC agents specific for 
single amino acid point mutations in proteins, which have many applications in cancer detection 
and treatment.  Chapter 3 describes the use of a general all-chemical epitope-targeting strategy 
that can focus PCC agent development directly to a site of interest on a protein surface.  This 
technique utilizes a chemically-synthesized chunk of the protein, called an epitope, substituted 
with a click handle in combination with the OBOC in situ click chemistry libraries in order to focus 
ligand development at a site of interest.  Specifically, Chapter 3 discusses the use of this technique 
in developing a PCC agent specific for the E17K mutation of Akt1.  Chapter 4 details the expansion 
of this ligand into a mutation-specific inhibitor, with applications in therapeutics. 
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1.1 Protein-Catalyzed Click (PCC) Peptide Capture Agents 
for Biomarker Detection and Therapeutics 
Detecting cancer-associated biomarkers is a necessary step on the road to personalized 
medicine, as emerging therapeutics require the identification of specific patient populations that 
will respond to targeted therapies1.  Methods for protein biomarker detection are highly desirable 
for rapidly screening changes in protein mutation status, monitoring patient treatment2, and 
simple point-of-care diagnostics3.  Techniques that rely on detecting or monitoring protein levels 
mainly use antibodies for the capture and measurement of these proteins4.  Antibodies, however, 
are biological reagents that are inherently unstable, vary from batch to batch, can exhibit high 
levels of cross-reactivity with other antibodies, and are expensive to produce5.  Diagnostic assays 
are frequently prohibitively limited in both cost and stability due to the restrictions of the gold-
standard antibody detection agents. 
Peptides can be the missing link for both inexpensive biomarker detection and targeting 
traditionally undruggable proteins.  Peptide - protein interactions cover a large surface area, 
producing antibody-like affinities with unsurpassed specificities6.  To date, most peptide discovery 
techniques use genetically-encoded libraries, which allow for ease of library generation and rapid 
and simple sequencing.  These techniques permit screening of enormous numbers of compounds 
against a target of interest without any complicated syntheses or detailed knowledge of the 
target7.  These libraries, however, are limited by the biological system from which they are 
derived, both in terms of screening elements and library size.  Most of these systems, such as 
phage display, bacterial display and yeast display, are confined to the natural amino acids because 
they use the cell machinery to make and express their libraries.  These systems limit the suitability 
of the resulting peptide capture agents due to the instability of biological peptides, which are 
comprised of naturally-occurring L -amino acid monomers that can be degraded in biological 
systems and fluids. 
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The Heath group has sought to alleviate the issue of peptide capture agent instability by 
relying exclusively on the use of unnatural amino acids.  Because biological libraries are not 
conducive to this type of work, we have instead adopted a peptide screening method utilizing 
One-Bead, One-Compound (OBOC)8 chemically synthesized libraries on 90μm polystyrene beads.  
This technique trivializes the inclusion of any unnatural amino acid or structure that can be 
chemically synthesized, allowing for the use of biologically stable D - amino acids and azide-alkyne 
click chemistry handles in the library9.   
The Sharpless group showed that the typical azide - alkyne click catalyst, Cu(I)10, speeds 
up the reaction but is only barely necessary for it to occur, and demonstrated the ability to replace 
this catalyst with the surface of a protein.  They took advantage of this to assemble small molecule 
inhibitors for proteins by breaking up known inhibitors into two components and assembling two 
libraries – each one comprised of pieces similar to its original half of the inhibitor.  One of these 
libraries of molecules was appended with a click handle, the other library with the opposite click 
handle.  When two click reactants bound tightly to the protein surface and in close enough 
proximity to each other, the long dwell time of these reagents allowed for the click to occur 
without the use of Cu(I)11.  In this way, they were able to bring the two libraries, which consisted 
of variations on the original inhibitor, together and use the surface of the protein to assemble the 
best possible small molecule inhibitor.   
We have adapted this technology to assemble 5-mer peptide sequences displayed on 
OBOC libraries using the surface of the target protein itself to catalyze a click reaction between 
peptides that bind tightly to this surface.  Hence, we have termed these capture agents “protein 
catalyzed capture” (PCC) agents.  This strategy requires that the two compounds are high-affinity, 
selective binders for the target that is acting as a catalyst because the click reaction does not occur 
without a long dwell time between the two agents.  PCC agents have been developed against a 
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number of protein targets, and have been shown to exhibit a selectivity and affinity similar to 
those of monoclonal antibodies.  They also can be readily integrated into all standard protein 
assay formats. 
Chapter 2 of this thesis describes the technology development process that was 
undertaken to optimize the screening stages for the production of high-affinity ligands to targets 
of interest.  Optimizing the in-depth screening procedure has allowed for the rapid expansion of 
this project in the past few years.  This detailed in situ azide-alkyne click screening technology is 
now regularly used to develop peptide affinity agents that mimic the performance of antibodies9-
15.  These affinity agents that maintain the stability of small molecules can be made to replace 
biological reagents9,12,15, lowering the cost and increasing the robustness of detection assays13,14. 
 
 
1.2 Epitope Targeting Strategies 
The detection of single amino acid point mutations in proteins is critical in the 
identification of specific patient populations that will respond to targeted therapies in the new 
era of personalized medicine1.  The current techniques for mutation detection rely on either 
capture and measurement of these proteins through antibodies,4 or on DNA sequencing.  DNA 
sequencing is currently an expensive and time-consuming route to take for mutation screening, 
especially as most patients need to be screened for mutations before the proper course of their 
treatment is even decided16.  Antibodies can provide a faster route for mutation detection and 
treatment monitoring, as there are methods currently in place for their use as rapid point-of-care 
diagnostics3.  These diagnostic tests also provide information about the levels of protein 
expression in a body, something that cannot be tested through sequencing, which can be used to 
monitor the response level of a patient to a certain treatment, potentially detecting ineffective 
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medications immediately after they are given.  In a diagnostic setting, such binders can be used 
to assay for the mutant protein within diseased tissues, and thus potentially provide clinical 
guidance for treatment decisions3.   
A more ambitious application is the development of drugs that can selectively inhibit 
mutant proteins, and thus avoid those toxic side-effects that stem from the inhibition of the wild-
type (WT) variants17 that reside in non-diseased tissues.  Patients on therapies targeted very 
specifically to the mutations characteristic of their disease could show significant improvements 
without the toxic side-effects that stem from of the inhibition of the healthy, wild-type versions 
of these proteins17.  A relevant example is compound CO-1686, which is an a epidermal growth 
factor receptor (EGFR) inhibitor specific for the T790M point mutation associated with certain 
non-small cell lung carcinomas.  That drug, which is currently in clinical trials, is designed to 
minimize the toxicities (such as skin rash) that can appear when WT EGFR is targeted, since WT 
EGFR is expressed throughout the healthy tissues in the body18.   
A challenge of drug targeting a single point mutation is that the mutation may not be 
directly associated with a binding pocket.  The presence of a binding pocket is traditionally 
required for small molecule inhibitor development as is serves as a thermodynamic sink that can 
attract binders.  This requirement does not hold for antibodies and, in fact, several examples of 
monoclonal antibodies directed against epitopes containing single amino acid mutations do 
exist19,2,20.  However, antibodies do not readily enter the living cells that can harbor the mutated 
proteins21,22, and so, mutation-selective antibodies are typically only used as diagnostic reagents 
for staining fixed cells or tissues.   
Thus, there is a need for an approach that can identify small molecules that can be 
generally targeted against epitopes containing single amino acid point mutations to allow for the 
rapid detection and assessment of tumor status, and can also potentially be developed into cell-
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penetrant inhibitors5.  Our approach is inspired by the technique for developing an epitope-
targeted monoclonal antibody (mAb).  Such mAbs are made by injecting a small portion of the 
protein of interest containing the mutation (the epitope) into an animal and screening for an 
immune response that has the desired selectivity2,20,19.  This approach can yield an antibody that 
exhibits focused binding to the specific designated area of the protein surface. 
An all-chemical strategy for targeting PCC agent development against epitopes near 
phosphorylates sites was developed recently15.  For that approach, an approximately 30-amino 
fragment representing the phosphorylated epitope of interest was synthesized, and a 
metalloorganic Zn-chelator was utilized to bind to the phosphate group and present an azide near 
that site.  That epitope was then screened against a large (1 million element) one-bead-one-
compound (OBOC) library of 5-mer alkyne-presenting peptides.  Hits were defined as those 
compounds that bound to the synthesized epitope, and that were coupled to that epitope through 
a triazole linkage.  PCC Agents with high selectivity for the epitope and the full protein, and with 
affinities as low as 19nM, were developed.   
The bulk of my thesis work focuses on the generalization of the epitope targeting strategy 
by directly substituting an alkyne click handle into the chemically synthesized peptide epitope 
(around the E17K residue of Akt1) of interest.  Chapter 3 describes how this technique was used 
to develop a 5-mer PCC agent selective for the E17K mutant Akt1 protein.  This PCC agent was 
able to be used as a drop in antibody replacement for the detection of this single amino acid 
mutation in various assays.  It was also possible to render this agent cell-membrane permeable, 
and this allowed it to be used as a focused imaging agent in live cell experiments.  Chapter 4 
describes the expansion of this PCC agent into a biligand and then a triligand through the use of 
iterative in situ click chemistry in order to make a bulkier PCC agent.  The final triligand PCC agent 
is capable of blocking the binding of the mutant protein to its substrate at the cell membrane, 
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rendering it inactive and demonstrating the ability of these PCC agents to serve as targeted 
therapeutics. 
 
1.3 In Situ Click Screening Using Azide-Containing Phage 
Display Libraries 
Peptide screening technology has expanded incredibly in the past ten years since the 
inception of the PCC agent project.  Using the protein-catalyzed click screens described above, 
PCC agents have been developed against only small chunks, or “epitopes” of proteins15,  and 
various PCC agents that have shown to be unique inhibitors and activators of Akt kinase23,15, 
molecular imaging agents24, detection agents for anthrax14, suitable as third world detection 
agents for HIV13, as well as the single amino acid point mutation specific E17K agents. 
The OBOC libraries have their drawbacks, however.   The physical size of the library limits 
the number of total sequences that can be screened.  A full library usually contains up to 106 
members – only a portion of which are screened.  The library screening and hit picking methods 
are exceptionally time-consuming and labor-intensive, hindering rapid peptide discovery.  The 
sequencing of OBOC libraries is also done by either Edman degradation or MALDI TOF/TOF, 
rendering the sequencing process expensive, time-consuming, and reliant on expert knowledge.  
Many of these drawbacks are also a huge barrier to entry in this field, limiting the labs that would 
be able to assist in the advancement of the science.  PCC agents could be produced significantly 
faster and cheaper with library display technology that would combine the advantages of the 
OBOC product screening techniques and library design with the rapid screening and sequencing 
of genetically displayed libraries.   
Recent advances in biology have made it possible to incorporate unnatural amino acids 
into the genetic code25.  Schultz has shown that through the use of amber suppression, azide-
containing amino acids can be incorporated in specific locations into the pIII coat protein on an 
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M13 phage26.  The Methanococcus jannaschii amber suppressor tRNATyr (MjtRNA) and the 
mutant M.jannaschii tyrosyl-tRNA synthetase (MjTyrRS) DNA can be contained in one plasmid 
that can be used to express these amber suppression tools in E.coli.  In this system, the mutant 
synthetase is used to attach the unnatural amino acid azidophenylalanine to the tRNA in vivo, 
allowing for its incorporation into proteins.  This tRNA recognizes the amber stop codon and 
should insert the amino acid in only that location, creating a new amino acid/tRNA combination 
that can be encoded into proteins. 
Chapter 5 discusses the ongoing development of a screening technology that combines 
the in situ click screen advantages of the OBOC process with the rapid screening of large libraries 
characteristic of biological display systems.  For this project, a phage display library containing 
azidophenylalanine for use in in situ click chemistry screening has been made and is being used 
to develop a PCC agent.  These phage libraries can be screened in place of the OBOC peptide 
libraries described in previous chapters for the more rapid development of PCC agents. 
 
1.4 References 
1. Hanash, S. M.; Baik, C. S.; Kallioniemi, O., Emerging molecular biomarkers--blood-based 
strategies to detect and monitor cancer. Nature reviews. Clinical oncology 2011, 8 (3), 142-50. 
2. Yu, J.; Kane, S.; Wu, J.; Benedettini, E.; Li, D.; Reeves, C.; Innocenti, G.; Wetzel, R.; 
Crosby, K.; Becker, A.; Ferrante, M.; Cheung, W. C.; Hong, X.; Chirieac, L. R.; Sholl, L. M.; Haack, 
H.; Smith, B. L.; Polakiewicz, R. D.; Tan, Y.; Gu, T.-L.; Loda, M.; Zhou, X.; Comb, M. J., Mutation-
Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer. Clinical 
Cancer Research 2009, 15 (9), 3023-3028. 
3. Rusling, J. F.; Kumar, C. V.; Gutkind, J. S.; Patel, V., Measurement of biomarker proteins 
for point-of-care early detection and monitoring of cancer. Analyst 2010, 135 (10), 2496-2511. 
4. Borrebaeck, C. A., Antibodies in diagnostics - from immunoassays to protein chips. 
Immunology today 2000, 21 (8), 379-82. 
5. Kodadek, T.; Reddy, M. M.; Olivos, H. J.; Bachhawat-Sikder, K.; Alluri, P. G., Synthetic 
molecules as antibody replacements. Accounts of chemical research 2004, 37 (9), 711-8. 
6. Edwards, P. J.; LaPlante, S. R., Peptides as Leads for Drug Discovery. In Peptide Drug 
Discovery and Development, Wiley-VCH Verlag GmbH & Co. KGaA: 2011; pp 1-55. 
7. Sun, N.; Funke, S. A.; Willbold, D., Mirror image phage display – Generating stable 
therapeutically and diagnostically active peptides with biotechnological means. Journal of 
Biotechnology 2012, 161 (2), 121-125. 
  23 
8. Lam, K. S.; Lebl, M.; Krchňák, V., The “One-Bead-One-Compound” Combinatorial Library 
Method. Chemical Reviews 1997, 97 (2), 411-448. 
9. Agnew, H. D.; Rohde, R. D.; Millward, S. W.; Nag, A.; Yeo, W.-S.; Hein, J. E.; Pitram, S. M.; 
Tariq, A. A.; Burns, V. M.; Krom, R. J.; Fokin, V. V.; Sharpless, K. B.; Heath, J. R., Iterative In Situ 
Click Chemistry Creates Antibody-like Protein-Capture Agents. Angewandte Chemie 
International Edition 2009, 48 (27), 4944-4948. 
10. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse Chemical Function from 
a Few Good Reactions. Angewandte Chemie International Edition 2001, 40 (11), 2004-2021. 
11. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radić, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; 
Sharpless, K. B., Click Chemistry In Situ: Acetylcholinesterase as a Reaction Vessel for the 
Selective Assembly of a Femtomolar Inhibitor from an Array of Building Blocks. Angewandte 
Chemie International Edition 2002, 41 (6), 1053-1057. 
12. Millward, S. W.; Henning, R. K.; Kwong, G. A.; Pitram, S.; Agnew, H. D.; Deyle, K. M.; Nag, 
A.; Hein, J.; Lee, S. S.; Lim, J.; Pfeilsticker, J. A.; Sharpless, K. B.; Heath, J. R., Iterative in situ click 
chemistry assembles a branched capture agent and allosteric inhibitor for Akt1. Journal of the 
American Chemical Society 2011, 133 (45), 18280-8. 
13. Pfeilsticker, J. A.; Umeda, A.; Farrow, B.; Hsueh, C. L.; Deyle, K. M.; Kim, J. T.; Lai, B. T.; 
Heath, J. R., A Cocktail of Thermally Stable, Chemically Synthesized Capture Agents for the 
Efficient Detection of Anti-Gp41 Antibodies from Human Sera. PLoS ONE 2013, 8 (10), e76224. 
14. Farrow, B.; Hong, S. A.; Romero, E. C.; Lai, B.; Coppock, M. B.; Deyle, K. M.; Finch, A. S.; 
Stratis-Cullum, D. N.; Agnew, H. D.; Yang, S.; Heath, J. R., A Chemically Synthesized Capture 
Agent Enables the Selective, Sensitive, and Robust Electrochemical Detection of Anthrax 
Protective Antigen. ACS Nano 2013, 7 (10), 9452-9460. 
15. Nag, A.; Das, S.; Yu, M. B.; Deyle, K. M.; Millward, S. W.; Heath, J. R., A Chemical Epitope-
Targeting Strategy for Protein Capture Agents: The Serine 474 Epitope of the Kinase Akt2. 
Angewandte Chemie International Edition 2013, 52 (52), 13975-13979. 
16. Mardis, E. R., A decade's perspective on DNA sequencing technology. Nature 2011, 470 
(7333), 198-203. 
17. Chong, C. R.; Janne, P. A., The quest to overcome resistance to EGFR-targeted therapies 
in cancer. Nat Med 2013, 19 (11), 1389-1400. 
18. Tjin Tham Sjin, R.; Lee, K.; Walter, A. O.; Dubrovskiy, A.; Sheets, M.; St Martin, T.; 
Labenski, M. T.; Zhu, Z.; Tester, R.; Karp, R.; Medikonda, A.; Chaturvedi, P.; Ren, Y.; Haringsma, 
H.; Etter, J.; Raponi, M.; Simmons, A. D.; Harding, T. C.; Niu, D.; Nacht, M.; Westlin, W. F.; Petter, 
R. C.; Allen, A.; Singh, J., In vitro and In vivo Characterization of Irreversible Mutant-Selective 
EGFR Inhibitors that are Wild-type Sparing. Molecular Cancer Therapeutics 2014. 
19. Capper, D.; Zentgraf, H.; Balss, J.; Hartmann, C.; von Deimling, A., Monoclonal antibody 
specific for IDH1 R132H mutation. Acta neuropathologica 2009, 118 (5), 599-601. 
20. Capper, D.; Preusser, M.; Habel, A.; Sahm, F.; Ackermann, U.; Schindler, G.; Pusch, S.; 
Mechtersheimer, G.; Zentgraf, H.; von Deimling, A., Assessment of BRAF V600E mutation status 
by immunohistochemistry with a mutation-specific monoclonal antibody. Acta neuropathologica 
2011, 122 (1), 11-9. 
21. Marschall, A. L. J.; Frenzel, A.; Schirrmann, T.; Schüngel, M.; Dubel, S., Targeting 
antibodies to the cytoplasm. mAbs 2011, 3 (1), 3-16. 
22. Rondon, I. J.; Marasco; A., W., Intracellular AntibodiesS (Intrabodies) For Gene Therapy 
Of Infectious Diseases. Annual Review of Microbiology 1997, 51 (1), 257-283. 
23. Millward, S. W.; Henning, R. K.; Kwong, G. A.; Pitram, S.; Agnew, H. D.; Deyle, K. M.; Nag, 
A.; Hein, J.; Lee, S. S.; Lim, J.; Pfeilsticker, J. A.; Sharpless, K. B.; Heath, J. R., Iterative in Situ Click 
  24 
Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1. Journal of the 
American Chemical Society 2011, 133 (45), 18280-18288. 
24. Millward, S. W.; Agnew, H. D.; Pitram, S.; Lai, B. T.; Rohde, R. D.; Hardman, N., Protein 
catalysed capture agents for molecular imaging. Internation Hospital Equipment and Solutions 
2013. 
25. Wang, L.; Xie, J.; Schultz, P. G., Expanding the Genetic Code. Annual Review of Biophysics 
and Biomolecular Structure 2006, 35 (1), 225-249. 
26. Tian, F.; Tsao, M. L.; Schultz, P. G., A phage display system with unnatural amino acids. J 
Am Chem Soc 2004, 126 (49), 15962-3. 
  





 Chapter 2 
 





  26 
2.1 Introduction 
2.1.1 Iterative In Situ Click Chemistry for Protein-Catalyzed Capture (PCC) Agent 
Development 
Previous work in the Heath lab demonstrated that the flexibility of chemically synthesized 
One-Bead, One-Compound (OBOC) peptide libraries could be combined with the selective power 
of the in situ click process to develop multi-peptide ligand capture agents that can serve as drop-
in antibody replacements in assays1.  These peptide ligands can be made in large quantities 
entirely by robots, making the scale-up cheap and robust.  They are also highly stable agents that 
can be used in a variety of assays, removing the need for the gold-standard antibodies in a variety 
of protein detection techniques2,3.  
The iterative in situ click screen to develop a capture agent starts with the discovery of a 
peptide ligand that binds to a protein target through the use of OBOC library screening.  Once a 
peptide has been discovered, labeled the “anchor peptide,” it is appended with a click handle and 
screened again against the protein in the presence of a new OBOC library that contains the 
opposing click handle, as seen in Figure 2-1.  When a library member binds to the surface of the 
protein in close proximity to the anchor ligand and is held in place through a high-affinity for the 
protein target, a click reaction between the anchor and library-bound ligand can occur without 
the use of the Cu(I) catalyst.  The addition of this new ligand, the secondary ligand, forms a 
“biligand” in complex with the original anchor.  This selection technique allows the protein target 
itself to catalyze the formation of the peptide ligands that bind to it with the highest affinity and 
selectivity.  This iterative process can be performed as many times as necessary to produce a 
ligand with the desired affinity and specificity for the target, and serves as the basis for the 
iterative in situ click chemistry technique for protein-catalyzed capture (PCC) agent production.  
After a PCC agent has been discovered using this technique, the Cu(I) catalyst can be brought back 
in order to scale-up the final click triazole-containing product in high quantities. 
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The technology as presented by Agnew, et al1 provided a solid foundation for the 
construction of these PCC agents, but the methods, discussed in section 2.3.1, were time-
consuming and labor-intensive, making rapid ligand discovery very difficult.  After this BCAii proof-
of-concept PCC agent was completed, the next stage of technology development required an 
optimization of the techniques involved in order to increase the robustness and output of the 
overall process.  This chapter describes the transformation of the OBOC iterative in situ click 
technology into an efficient and robust technique. 
 
2.1.2 Prostate Specific Antigen (PSA) 
Prostate Specific Antigen (PSA) is a serum protease produced by the prostate.  The 
accurate detection of PSA levels in the blood can be a strong indicator of the presence of prostate 
cancer, but this result is confounded by the elevated PSA levels also seen in Benign Prostate 
Hyperplasia (BPH), a non-cancerous condition4.  In serum, PSA is partially in complex with α1-
antichymotrypsin (ACT), with 60-95% generally found as a PSA-ACT complex while the rest of the 
PSA remains free.  It has also been discovered that the PSA-ACT fraction is larger in prostate 
cancer, whereas BPH has more PSA free in serum4.  It was hypothesized, therefore, that a better 
PSA detection test could be designed to measure this through the use of PCC agents, and much 
of the screening strategies developed in this chapter were focused on the design of this agent. 










Figure 2-1: Iterative In Situ Click Screening Core Technology. 
 An anchor ligand that binds to the protein target can be appended with a click handle.  In the presence 
of the protein and a OBOC library appended with the opposite click handle, the anchor can click onto 
the library to form a biligand.  The click only occurs when the anchor and library bead are held long 
enough on the protein surface, so the protein selects ligands with high affinities and selectivities.  This 
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2.2 Materials and Methods 
2.2.1 Standard Materials 
All amino acids were purchased from Aapptec as the FMOC carboxylic acid with the 
standard TFA side-chain protecting groups.  HATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate) and PEG5 (Fmoc-NH-PEG5-CH2CH2COOH, Fmoc-18-
amino-4,7,10,13,16-pentaoxaoctadecanoic acid) were purchased from ChemPep.  DIEA 
(diisoproylethylamine), TES (triethylsilane), and TFA (trifluoroacetic acid) were purchased from 
Sigma.  TentaGel beads were purchased as 90μm S-NH2 beads, 0.29mmol/g, 2.86x106 beads/g 
from Rapp Polymere (Germany), and Rink Amide resin was purchased from Anaspec. 
 
2.2.2 Peptide Library Construction 
Peptides and peptide libraries were synthesized by 
hand until the summer of 2009, when they were then 
synthesized on a Titan 357 split-and-mix automated peptide 
synthesizer (Aapptec) via standard FMOC SPPS coupling 
chemistry5 using 90μm TentaGel S-NH2 beads.  Libraries 
contain 18 D-stereoisomers of the natural amino acids, minus cysteine and methionine (unless 
otherwise stated), at each of five randomized positions and an azide or alkyne in situ click handle.  
At least a five-fold excess of beads is used when synthesizing libraries to ensure efficient 
oversampling of each sequence.  Amino acid side-chains are protected by TFA labile protecting 





Figure 2-2: OBOC Peptide Library 
constructed on TentaGel Resin. 
Where X is comprised of all of the 
naturally occurring D – amino 
acids except Cys and Met. 
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2.2.3 Bulk Peptide Synthesis 
Bulk synthesis of peptide sequences was performed using standard FMOC SPPS peptide 
chemistry on either the Titan 357 automated peptide synthesizer (AAPPTEC) or a Liberty 1 
microwave peptide synthesizer (CEM Corporation).  The typical scale was 300mg on Rink Amide 
Resin, unless otherwise noted.  Peptides were cleaved from the beads with side-chains 
deprotected using a 95:5:5 ratio of TFA: H2O: TES.  The peptides were purified on a prep-scale 
Dionex U3000 HPLC with a reverse-phase C18 column (Phenomenex). 
 
2.2.4 Typical Screening Protocol for Fluorescent Dye-labeled Protein Target 
Detection 
Hit beads in the initial OBOC screens were detected via a fluorescent probe attached to 
the protein target of interest.  The target protein was labeled using an Alexa-Fluor 647 Microscale 
Protein Labeling Kit, following all manufacturer’s instructions.  The activity of the target enzymes 
was then tested before screening to ensure that the dye label did not disturb function or folding. 
Screens were conducted using a OBOC library of 5-amino-acid-long peptides composed 
of the D - isomers of 19 naturally occurring amino acids (no Cys, for stability reasons).  100mg of 
dried library was weighed for screening (~280,000 unique sequences, ~42% sampling of sequence 
space) and swelled in 1xTBS buffer (25mM Tris, 150mM NaCl, 10mM MgCl2, pH = 7.5) containing 
0.05% NaN3, 0.1% BSA, and 0.1% Tween-20 (TBSTBNaN3).  The library was then blocked for one 
hour in this buffer, then 50nM protein in 1.5mL TBSTBNaN3 was added, the screen wrapped in foil 
to protect the light-sensitive dye label, and incubated overnight on a 180° shaking arm.  In the 
morning, the buffer containing the protein was drained from the beads, which were then washed 
three times with TBSTBNaN3, three times with TBS + 0.1% Tween-20 (TBST), then three times with 
1xTBS.  The beads were then dried on a vacuum and spread to a monolayer on approximately 10 
clean microscope slides for about 10mgs of beads per slide.  The slides were imaged on a GenePix 
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Pro 5.1 microarray scanner at 635nm to view beads containing bound fluorescent protein target.  
The dye saturated the color signal of the GenePix, and the hit “beads” that were considered 
appeared white in a sea of red, due to the background auto fluorescence of the TentaGel library 
(Figure 2-4).  These hit beads were then removed from the microscope slides using a needle, 
stripped of protein with 7.5M pH = 2.0 Guanadine-HCl buffer, rinsed in water, and sequenced via 
Edman degradation on an Applied Biosystems Procise CLC 494 system. 
 
2.2.5 Typical Screening Protocol for Antibody Signal Amplification Target Only 
Screens 
100mg of library beads were prepared, washed and blocked for one hour as for the 
fluorescent detection screen.  The library was then incubated with about 50nM, which differed 
slightly based on the exact screen, of protein overnight at room temperature.  In the morning, the 
library was washed five times with 1xTBS + 0.1% BSA + 0.1% Tween-20 (1xTBSTB).  The primary 
anti-protein target antibody was incubated with the library for 1 hour, washed five times with the 
1xTBSTB buffer, then incubated with the secondary anti-mouse alkaline-phosphatase antibody 
for one hour.  The library was then washed five times with the TBSTB buffer, three times five 
minutes each in high salt buffer (1xTBS + 600mM NaCl), and five times in 1xTBS.  The screen was 
developed with a two part BCIP/NBT system: 10mL TBS + 26 μL BCIP + 13 μL NBT.  This detection 
cocktail was mixed with the library beads, which were poured into a large polystyrene dish for 
visualization of the color change under an optical microscope.  Hit library members appear as dark 
purple among the normally clear beads (Figure 2-6), and are removed using a pipet.  They are 
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2.2.6 Typical Screening Protocol for an Anti-Screen 
The library beads (typically 250-500mg) swelled in 1xTBS were blocked 2 hours to 
overnight in 5% milk in 1xTBS, washed three times with 1x TBS, then incubated with an off-target 
protein in 0.5% milk in 1xTBS for one hour on the shaking arm at room temperature.  The beads 
were washed three times with 1x TBS, then incubated with the anti-off-target protein - alkaline 
phosphatase conjugated antibody in 0.5% milk for one hour at room temperature.  The antibody 
used here must be the same antibody used in the target screen in order to ensure that the library 
members that bind to this antibody are removed and not mistaken for hits.  The library resin was 
then washed three times with high salt buffer and let shake for one hour in high salt at room 
temperature before being washed three times with BCIP buffer (100mM Tris-Cl, 150mM NaCl, 
1mM MgCl2, pH = 9.0) and developed by adding 15mL BCIP buffer plus 13μL BCIP and 26μL NBT.  
The beads that turned purple bound to both mutant and wildtype protein or to the detection 
antibodies, and were discarded.  The beads that remained clear after this step were picked and 
washed with guanidine-HCl to remove any bound proteins. 
The off-target protein can be a different version of the target, such as a wildtype protein 
when detecting for a mutation, or a protein lacking a certain domain or post-translational 
modification of interest, such as a phosphorylation site or glycosylation.  Anti-screens can also be 
designed to clear against any number of interferents, such as whole human serum, to remove any 
generally sticky peptide sequences.  For these anti-screens, the antibody used for detection is an 





  33 
2.2.7 Typical Target Screening Procedure During a Multi-Step Screen (Figure 2-3) 
The library beads were blocked in 5% milk in 1x TBS for two hours to overnight.  They 
were then washed three times with 1x TBS.  The target protein and anchor peptide or small 
molecule targeting agent6 were pre-incubated in 3-5mL of 0.5% milk in an approximately a 10:1 
ratio, ensuring the same concentration of anchor peptide used in the preclear.  This solution was 
added to the blocked library beads and incubated for either 5 hours or overnight to allow an in 
situ click reaction to occur.  In the morning, the beads were washed three times with 1x TBS, then 
incubated with the same dilution of an anti-target alkaline phosphatase conjugated antibody that 
was used in the anti-screen in 0.5% milk for one hour.  The beads were then washed three times 
with a high salt TBS, then incubated on the shaking arm for one hour with the high salt buffer.  
They were then washed three times with BCIP buffer and developed as previously.  Hit beads 
turned purple and were removed and washed in NMP for four hours to decolorize, then 
guanidine-HCl to denature and remove and remaining protein.   
 
2.2.8 Typical Screening Protocol for a Preclear 
Swelled library beads (250-500mg) were blocked overnight in 5% w/v dried non-fat milk 
in 1x TBS, then washed with 1x TBS three times.  The beads were incubated with a μM solution of 
any anchor peptide or small molecule for one hour, then washed 3x with 1xTBS.  Five milliliters of 
either a 1:10,000 dilution of streptavidin-alkaline phosphatase conjugate in 0.5% milk in TBS or an 
anti-biotin antibody were added to the beads and incubated with shaking at room temperature 
for one hour.  If the anti-biotin antibody was used, a secondary antibody conjugated to alkaline 
 
Figure 2-3: Typical Antibody-Detected Target Screen.  The library is incubated with the protein target, which is detected 
via antibodies conjugated to alkaline phosphatase.  The screen is developed with BCIP/NBT, and hit beads turn purple. 
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phosphatase was then incubated with the library for 1 hour after it was washed three times in 
1xTBS.  The beads were washed with a high-salt TBS buffer three times, then were left to shake 
in high salt buffer for one hour.  The beads were then washed three times with BCIP and 
developed as for the anti-screen.  After one hour, the purple beads were removed by pipette and 
discarded.  The remaining beads were incubated in NMP 4 hours to remove trace purple 
precipitate from the BCIP/NBT reaction, then were washed five times with methanol, five times 
with water, five times with TBS and blocked overnight in 5% milk. 
 
2.2.9 Typical Screening Protocol for a Click Product Screen 
The beads that pass through the target and anti-screen were washed three times with 1x 
TBS.  They were then incubated with a 1:10,000 dilution of either streptavidin – alkaline 
phosphatase conjugate or anti-biotin antibody (whichever was used in the preclear) in 0.5% milk 
for one hour.  The beads were washed three times with high salt TBS then let shake for one hour 
with high salt buffer before being washed three times with BCIP buffer and developed as 
previously.  The beads that turned purple contained the anchor peptide covalently bound to the 
bead and had formed a protein-catalyzed in situ click reaction.  These beads were collected and 
stripped with guanidine-HCl for one hour, washed ten times with water, and sequenced via Edman 
degradation. 
 
2.2.10 Peptide Sequencing Strategies 
The OBOC peptide library sequencing method most commonly used by Caltech is Edman 
degradation.  This process involves treating a peptide with a free amine terminus with 
phenylisothiocyanate, which reacts stoichiometricly with the N-terminus of the peptide to form a 
phenylthiocarbamyl (PTC)-peptide derivative.  This PTC derivative is then treated with TFA to 
cleave it off from the rest of the peptide, leaving behind a new N-terminus to react during the 
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next cycle.  Meanwhile, the PTC amino acid is then analyzed via HPLC, and the peak is compared 
to standards of all of the PTC-amino acids in order to determine the residue.  One cycle per amino 
acid residue is performed and analyzed, providing the sequence of the peptide on the hit library 
bead7.  This method is slow, but highly accurate and has been automated by Applied Biosystems 
into the Procise CLC 494 Automated Edman Degradation machine used by Caltech. 
 Hit peptide sequences can also be determined through MALDI-TOF/TOF MS.  For this 
method, the library must be specially made.  The peptide must be attached to the library through 
a methionine amino acid, and no other methionine can be present in the library.  The isobaric 
amino acids, isoleucine and leucine, lysine and glutamine, are doped by anther amino acid in order 
to properly call the sequence by mass.  Glutamine is doped with a 6% molar equivalent of glycine, 
and isoleucine is doped with a 7% molar equivalent of alanine.  While reading the mass of these 
amino acids on the MALDI, any residue that has one of these amino acids can be distinguished by 
the presence or absence of the small satellite parent mass corresponding to the same sequence 
plus glycine or alanine8. 
 In order to sequence the library hit by MALDI-TOF/TOF, the bead is first treated with 
cyanogen bromide in order to cleave the peptide from the bead at the methionine amino acid.  It 
can then be dissolved in MALDI matrix and spotted onto the plate.  The peptide parent peak is 
first discovered using MALDI-TOF, then is fragmented again in order to break it up into smaller 
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2.3 Results and Discussion 
2.3.1 Screening via Fluorescent Dye-labeled Protein Target Detection 
The initial OBOC peptide screening strategies 
developed by Heather Agnew1 relied on a fluorescent 
dye-labeled protein in order to detect hit binding.  The 
target protein of interest was labeled with a dye, and any 
library beads that bound to the target were detected on 
a GenePix microarray reader.  As seen in Figure 2-4, the 
TentaGel library beads also auto-fluoresce, meaning that 
all screens conducted in this fashion were highly 
subjective, and the hit quantity depended entirely on the 
gain settings of the microarray.  AlexaFluor-647 was also 
the only dye that was used, as the beads auto fluoresce 
the least in the range of this dye.   These hits were mostly 
picked using a light microscope, meaning that the images 
from the microarray had to be used as a “map” to guide 
the bead picker to the correct clear bead on a slide of thousands.  This process was highly 
inefficient, requiring up to an hour to pick each individual hit bead.  These picked hits were always 
imaged again on the GenePix to ensure that each bead that had been selected was a highly 
fluorescent bead, indicating that the correct one had been chosen based on the map.  It was 
possible to use a COPAS automatic bead sorter to separate out the hit beads, though one was not 
available at Caltech. 
The sequences from a typical fluorescent target screen are shown in Table 2-1.   The hits 
were generally dominated by the positively charged residues, arginine and lysine.  This 
overwhelming charged signal is most likely due to the overall (-3) charge on the AlexaFluor 647 
 
Figure 2-4: Image of Hit Beads on GenePix 
Microarray Scanner.  The bright white beads 
are saturating the fluorescence and are 
considered “hits” above the background 
TentaGel auto fluorescence. 
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dye,9 which is attracting the positively charged amino acid sequences and creating a significant 
level of noise in the final hits.  Most screens had to be run many times in order to find enough 
quality hit sequences, meaning ones that did not contain almost exclusively arginine and lysine 
residues, because of this high background.  Generally, a hit that contained 3 or more positively 
charged amino acids was considered background and removed from the pool.  One screen rarely 
yielded more than a handful of hits that appeared to be binding to the surface of the protein and 
not just to the dye. 
Focused screens were also 
used in order to hone in on target-
binding peptide sequences.  The 
focused libraries used in these screens 
were designed based on histograms of 
the amino acids that were seen at each 
library position, meaning X1 -> X5 as 
seen in Figure 2-2, after the removal of 
the dye label background sequences.  As can be seen in Figure 2-5, in this particular PSA screen, 
there were only six amino acids that were seen at position 2, so only these six amino acids were 
built into the focused library at position 2. This reduction in total amino acids present in each 
position allowed for the synthesis of a much smaller library that could be oversampled in each 
screen to permit a more thorough sampling of the sequence space.  Only about 100mg of beads 
were usually screened, but 100mg could frequently oversample the sequence space of a focused 
library, compared to that of naïve libraries where less than half of the space was sampled.  Due 
to this increase in sequence space sampling, focused libraries were generally extended by one or 
two amino acid positions in the hopes that a slightly longer peptide would have a higher affinity 
 
Figure 2-5: Histogram of Position X2 in PSA Screens.  The hits from 
multiple PSA screens were pooled and analyzed.  This sample chart 
shows the frequency of an amino acid at position X2 in the library, 
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and selectivity for the protein target.  The screening was then repeated with the focused libraries, 
and the same process for analyzing hits was repeated until the peptide sequences converged in 
sequence homology and produced a peptide ligand that showed near μM affinity for the protein 
target.   
This convergence frequently required the use of two to three separate focused libraries 
with accompanying screening and sequencing.  The overall time required to determine one 
peptide ligand that bound to the target protein of interest could easily take more than six months.  
These ligands also regularly bound in the range of low μM affinities, which are generally 





Table 2-1: Screens from Sample Target Screen Using Fluorescent Protein Detection.  This screen 
was performed against PSA protein labeled with AlexaFluor 647 dye.  Note the high prevalence of “r” and “k” 
positively charged amino acids.  See Figure 2-2 for a visualization of the X amino acid positions on bead. 
X1 X2 X3 X4 X5 
y r r r r 
r i f r r 
r f l r a 
r r k r f 
m r r w r 
r r r w p 
r r w i r 
r r r f l 
r l r w r 
r f r i r 
l s r r r 
r r r y t 
r r m r w 
r r k p r 
f y r r r 
r k w l w 
k r r m r 
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2.3.2 Screening via Antibody Signal Amplification Target Only Screens 
Detecting hit peptides via fluorescence was a very time-consuming process in which the 
high noise from the overwhelming 
presence of positively charged amino acids 
meant that very little meaningful output 
was obtained.  For this reason, a new 
method of screening was developed using 
a tag-less protein to switch the screening 
focus from the charged dye label back to 
the target.  This technique relied on anti-target antibodies conjugated to alkaline phosphatase, 
which is an enzyme that can form a dark purple precipitate in the presence of its BCIP/NBT 
substrate.  This meant that any “hit” now showed up as a very dark purple bead in a sea of clear.  
The label-less detection technique, therefore, provided the additional benefit of a colorimetric 
readout of a hit, allowing for the much easier separation of these beads from the rest of the 
library.   
As can be seen in sample screen results in Table 2-2, the high prevalence of positively 
charged amino acids is gone.  In fact, the comparison between Table 2-1 and Table 2-2 is startling, 
considering that the only difference between these two screens is the target detection method.  
This demonstrates that the dye label was having a dramatic effect on the quality of hit sequences 
and was responsible for much of the large time investment that was devoted to screening.  This 
huge reduction in noise now meant an instant reduction in the number of screens that needed to 
be run and sequenced in order to see homology.  The colorimetric hit visualization also permitted 
larger numbers of beads to be screened much faster, so the overall number of library sequences 
that were sampled went up even though fewer screens were run.  One BCIP/NBT-developed 
screen could sample the same number of beads as up to five different fluorescent screens in less 
 
Figure 2-6: Image of Hit Bead Developed with BCIP/NBT.  
High background lighter purple surrounding beads could be 
removed through later preclear and antiscreen steps. 
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time, as all of the hits could be picked in the time it used to take to pick one.  With this increase 
in both sampled sequence space and in the overall signal to noise seen in the sequences, hit 
quality and screening speed improved dramatically in a much shorter overall time. 
 
 
2.3.3 Introduction of an Anti-screen 
The antibody development technique dramatically improved the quality of hit peptides 
by visual inspection (Table 2-1 versus Table 2-2), but also introduced a hidden source of noise into 
the screens.  The presence of several different antibodies and a new detection agent in the screen 
itself provided more “off-target” sources of library binding.  This was conclusively demonstrated 
by Steve Millward while screening for an Akt capture agent.  He developed a biligand using the 
standard in situ click chemistry technique with antibody development, and proceeded to test the 
affinity of this ligand via SPR.  The SPR was set up to immobilize an anti-FLAG antibody (the same 
used in screening) to the flow cell in order to capture the much less stable Akt protein that might 
Table 2-2: Screens from Sample Antibody Amplification Screen Using BCIP/NBT Protein 
Detection.  Screen was performed against unlabeled (PSA), detected with PS2 mouse mAb anti-PSA antibody 
and anti-mouse-AP secondary antibody with BCIP/NBT readout. 
X1 X2 X3 X4 X5 
n g m e d 
e t q m d 
w t d e m 
s e d d t 
a n d e e 
n y d p e 
G n m d d 
e d v l i 
f e n d a 
e i n e l 
v e f G e 
e h d a y 
d e t a t 
i w n m e 
y d d s l 
d d e a G 
e n t i d 
  41 
not survive the required EDC/NHS coupling step.  A blank flow cell of only Anti-FLAG antibody 
without Akt was used as a chip blank.  The data from these SPRs is seen in Figure 2-7.  The 
sensorgram on the right shows binding to the Akt, as to be expected, but the sensorgram from 
the blank flow cell on the left shows an identical signal.  In conjunction with data (not shown) 
from the anchor ligand that has almost no binding to the anti-FLAG flow cell, we can conclude 
that the biligand is actually binding to the anti-FLAG antibody, present in both of those flow cells, 
and not to the desired Akt target protein.  It is only logical that we would see “hits” of peptide 
sequences that bind to these antibodies, because the presence of the detection antibody bound 
to a library bead would show BCIP precipitation exactly like the presence of the target protein.  A 
new screening step was needed that would remove the signal seen from the binding of these 
other proteins used in the screening process. 
 
 Around this time, there was interest in developing capture agents for proteins containing 
post-translational modifications, such as phosphorylations or glycosylations.  It was hypothesized 
that hits specific for a post-translational modification could be discovered by screening against 
the protein target containing the modification, then anti-screening against the protein target with 
 
Figure 2-7: SPR Data from Akt Biligand. Data from Steve Millward’s Akt Biligand Capture Agent.  An anti-FLAG 
antibody was immobilized onto an SPR chip via standard EDC/NHS coupling techniques.  It was used to capture a FLAG-
tagged Akt protein for testing.  As seen from the figure on the left, the capture agent bound equally as well to the flow 
cell immobilized with only Anti-FLAG antibody, supposed to be the chip blank, as to the one on the right that also 
contained immobilized Akt indicating that the biligand’s affinity actually stems from the Anti-FLAG antibody and not the 
Akt protein target. 
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the post-translational modification removed, since everything else in the screen would be 
identical (Figure 2-8).  These screens entailed first “target screening,” as per usual antibody 
detection screens, to find all of the hit beads that have an affinity for the target.  These beads 
were then be stripped of their purple color and bound proteins and incubated with the off-target 
protein that had the post-translational modification removed.  Any purple hits from the anti-
screen were thrown out as not specific for the modification, since they demonstrated binding in 
a screen that did not contain the site of interest.  This new screening step has the added benefit 
of removing all of the hits that also have an affinity for the antibodies or developing solution that 
was used in the screen.  An anti-screen like this would have prevented the development of a 
biligand with an affinity for the anti-FLAG antibody, as these hits would have been detected in 
both the target and the anti-target screen, and would have been discarded. 
 The anti-screen is an important step that is now incorporated into each screen that is run 
in the lab, and is responsible for a significant reduction in background hits.  For example, an anti-
screen that was run for the PSA protein eliminated 91% of the hit beads from the target screen, 
indicating that approximately 91% of what was previously considered to be a target hit was just 
background.  For visualization purposes (Table 2-3), this means that a screen run with 250mg of 
beads went from 167 hits down to 15 after this step.  This cut down on not only sequencing and 
hit analysis/testing time, but also eliminated the time that was usually spent trying to tease out 
signal from noise.  Focused screens were also no longer necessary, as that step was designed to 
help enrich for signal, eliminating a significant chunk of time necessary for developing a capture 
agent. 
Current screening protocols have evolved significantly to include stringent anti-serum 
anti-screens in order to make capture agents that can function in the most complex mediums, 
such as out of blood and in cells.  For these anti-screens, the decolorized target hit beads are 
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incubated with anywhere from 1% - 25% human serum to remove even the marginally sticky 
peptides from the pool of potential candidates.   
 
2.3.4 Introduction of a Click Product Screen 
The in situ screening process has an inherent screening advantage that had not yet been 
exploited.  A covalently-linked product is formed on the surface of the bead during the screen 
that can be detected separately from target binding.  This means that in addition to probing the 
library for beads that bind to the target, the library can be searched additionally for the presence 
of the in situ click product – a completely complementary screen.   
Once an anchor ligand has been discovered, the next step in the in situ screening process 
(Figure 2-1) involves the clicking of a new peptide ligand onto this anchor ligand.  In order to 
accomplish this, the anchor peptide is appended with a click handle and pre-incubated with the 
target protein, and then both are incubated with the OBOC library.  This step searches for a library 
peptide that binds in close proximity to the anchor peptide on the surface of the protein target, 
and will “click” onto the anchor if held in position long enough.  This click reaction covalently 
attaches the anchor peptide onto the library bead.  By first appending the anchor peptide with a 
biotin tag, the presence of the anchor peptide on bead, or the ability of this library candidate to 
“click” to the anchor, can be probed independently of the presence of the target on bead.  These 
screens involve harsh, denaturing wash steps that ensure that everything not covalently attached 
 
Figure 2-8: Sample Anti-Screen Step.  The target hits are stripped of target, decolorized, and incubated with an off-
target or general interferent such as human serum.  The off-target is detected with an off-target antibody (the target 
antibody should also be included if it is different), and these purple beads are non-specific binders, which are removed.  
The clear beads are specific for the target. 
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to the library will be removed and not detected by either the streptavidin conjugated to alkaline 
phosphatase or an anti-biotin antibody.  These detection agents will bind to the biotin label on 
the anchor that will only be present after a covalent reaction has occurred, and can therefore 
detect which library members have formed a click product (Figure 2-9). 
Continuing the comparison with the 
PSA screens from above, only 7 of the 15 
remaining beads after the anti-screen showed 
the presence of a click product.  The other 8 
beads could very easily have been hits that 
would be a different anchor ligand – a peptide ligand that is binding specifically to the target 
protein, but is not close enough to the original anchor for a click to form.  The sequences from 
these hits, shown in Table 2-4, are very nearly identical peptides, and contrast sharply with the 
previously identified hits from the anti-screen in Table 2-2.  This indicates that the sequences are 
more than likely all binding very strongly to the exact same location and in close proximity to the 
anchor ligand, allowing for the formation of the click product. 
 
The product screen is an elegant step in the screening process that allows for the very 
specific narrowing of the sequence space.  It has become such a huge part of the success of the 
OBOC capture agent development process that naïve anchor screens, which inherently cannot 
Table 2-3: PSA Screening Statistics.  These hit bead statistics 
are taken from a screen against PSA.  The percent column 
indicates the percent of beads that passed from one stage of 
the screen to the next. 
 Beads Percent 
Start 375,500  
Target Screen 167 0.04% 
Anti-screen 15 9% 
Product Screen 7 47% 
Table 2-4: PSA Hit Bead Sequences from Product Screen.  The product hits shown in Table 2-3 were 
sequenced.  There is an enormous sequence homology, meaning that the same part of the target is 
being targeted.  The end of the last sequence and the 7th hit were lost due to machine error. 
X1 X2 X3 X4 X5 
Y G w r e 
Y d w r q 
L G w r e 
e G w r e 
a d w r q 
a G - - - 
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include product screens, have been completely eliminated.  This switch to all in situ click screens 
has greatly increased both the specificity and affinity of the original anchor ligands, dramatically 
improving the quality of the final PCC agent.  Details of the rationale and results from these more 
targeted screens can be seen in Chapter 3. 
 
2.3.5 Introduction of a Preclear 
Three of the candidates from Table 2-4 were scaled up.  In order to do this, the secondary 
arm is clicked to the original anchor using Cu(I) to form a “biligand,” and is tested for binding to 
the PSA protein.  Unfortunately, none of the biligand candidates shown in Table 2-4 demonstrated 
binding to the PSA protein in either ELISA assays or SPR, even though the anchor ligand by itself 
was still able to bind (indicating that all of the parts of the assays were working).  The secondary 
ligands themselves also did not show any binding to the PSA protein, independent of the anchor 
ligand.  These ligand sequences from the click screen, however, were very homologous, indicating 
that they were all binding in the same place, which was somewhere they could click onto the 
anchor peptide.  It would be impossible to see that level of similarity in the hit sequences, 
otherwise.  Unfortunately, during the screening process, the anchor ligand itself is present in ten 
times higher quantity than the protein target, and can also bind to the library beads.  It was 
hypothesized, therefore, that the anchor ligand itself bound to those library sequences tightly 
enough to catalyze the click product that was detected in the final screen.  This scenario would 
 
Figure 2-9: Sample Product Screening Step.  The specific hits that survive the anti-screen are stripped of all non-covalent 
binders and incubated with anti-biotin alkaline phosphatase (or streptavidin).  The purple hits from this screen indicate 
those in which a click reaction has covalently attached the anchor ligand onto the library bead. 
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explain why the biligands showed no binding to the protein – the anchor could no longer even 
bind to the target with another ligand, potentially blocking those binding sites.  It also explains 
why the secondary ligands showed no affinity for PSA.  They were not ligands that bound to the 
target, and wouldn’t have an affinity for it. 
To counter this effect, a new screening step was added at the beginning of the process to 
remove all of the library peptides that bound to the anchor ligand before the anchor ligand even 
saw the target protein (Figure 2-10).  These screens still detect the biotin label on the anchor 
ligand, and the detection with streptavidin or anti-biotin in this “preclear” step eliminates the 
need to use these detection agents in the anti-screen.  The preclear screens generally remove 1-
10% of the library beads, depending on the library, and also reduce the percentage of beads that 
need to be removed in the anti-screen. 
 
2.3.6 Use of Alkyne Versus Azide Libraries 
Throughout the course of technology development, certain seemingly trivial details 
become important.  For the OBOC screens, different libraries and slightly different conditions 
produced vastly different results.  The first issue with the propargylglycine alkyne-containing 
amino acids surfaced initially after the addition of multiple stages to the screening process.  After 
undergoing more than three rounds of screening, washing and denaturing, the libraries containing 
the alkyne were no longer able to be successfully sequenced via any method - Edman degradation 
or MALDI TOF/TOF.  The Edman spectra were entirely blank, indicating that the amino acid 
 
Figure 2-10: Sample Preclear Screening Step.  The library is incubated with an anchor or biligand, which is then detected 
with an anti-biotin alkaline phosphatase conjugated antibody (or streptavidin), and developed with BCIP.  The purple 
beads from this screen bind to either the initial ligand or the detection antibody. 
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residues were probably not cleaving from the beads, and the MALDI TOF/TOF was unable to 
identify a parent peak that contained the fixed alkyne amino acid.  The alkyne-containing amino 
acid was the N-terminal residue, the first residue that needed to cleave via Edman, and anything 
modifying this amino acid would affect the cleavage.  It was hypothesized that the BCIP/NBT 
developing solution was modifying these amino acids, which was confirmed by the use of C-
terminal alkyne libraries.  Even after undergoing four screening steps, the libraries still sequenced 
correctly using Edman degradation up to the alkyne amino acid. These same library hits, though, 
were not able to be sequenced using MALDI-TOF/TOF.  Because the TOF/TOF would be greatly 
affected by an unknown change to an amino acid, it was assumed that the alkyne was somehow 
being modified during these screening steps.  For this reason, azide-containing libraries are now 
always used when undergoing more than three screening steps, unless a C-terminal alkyne library 
with Edman degradation sequencing is appropriate. 
It was also noticed that the libraries that contained a propargylglycine seemed to have 
more difficult preclears, meaning more purple hits to remove, than the libraries that contained 
the Lys(N3) azide amino acid.  To test this, two libraries, identical except for their N-terminal azide 
or alkyne click handle, were blocked in 5% milk in TBS.  The libraries were washed three times in 
TBS, then developed with the BCIP/NBT solution used in the methods section.  After 45 minutes, 
about 5% of the beads in the alkyne library turned bright yellow, indicating binding of the NBT 
substrate.  The azide library did not show this background substrate turnover/binding, and it was 
assumed that this was related to the sequencing issues with the alkyne libraries.  If the NBT 
substrate is somehow changing or appending to the propargylglycine amino acid, it could explain 
why the sequences no longer appear as they should during screening. 
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2.3.7 Typical Flow of Screening 
With a multi-stage screening process now in place, the some of the steps need to be 
conducted in a certain order to achieve the correct results.  The first step is the preclear.  This 
occurs before the anchor ligand sees the protein target, and has a chance to form legitimate 
clicked-hit peptides on bead.  These screens look for anything that binds to streptavidin, alkaline-
phosphatase, BCIP/NBT, and the anchor peptides.  Usually, a screen begins with 300-500mg of 
library beads, and 1-10% are removed.  Typically, any bead that has turned even the lightest shade 
of purple is removed in order to reduce the overall background as much as possible.  This means 
that any bead that passes through this stage of the screening process has remained clear. 
The next step is the target and click-catalyzed screen.  The beads that remained clear in 
the preclear are incubated with the target of interest and the anchor ligand overnight for a click 
reaction to occur.  These beads are then probed for the presence of target.  Any bead bound to 
target will turn purple, and passes through to the next stage of screening.  Even though the on-
bead click has occurred during this screen, probing for the click product occurs at a later stage. 
The hits from the target screen are then decolorized and incubated with an off-target 
protein or proteins.  Any library bead that binds and turns purple in this screen demonstrates off-
target interactions with other proteins, and is removed from the pool.  At the end of this screen, 
only beads that remain entirely clear are kept.  Even slight purple can indicate undesirable 
interactions and background binding, and are removed from the pool of hits. 
The final screening stage probes for the presence of the clicked product on bead.  After 
harsh denaturing and washing conditions, the beads are probed for the presence of biotin.  These 
beads will turn purple only if biotin is linked to the bead, which is only possible if the in situ click 
reaction was successful.  These purple hits have proven to have no affinity to the screening agents 
in the preclear, an affinity for the target but not off-target interactions in the target and anti-
screens, and then have also shown involvement in the covalent click reaction.  The clear-purple-
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clear-purple pattern of hit detection also ensures that the beads are behaving properly at each 
stage in the process.   
Screens following this pattern now have several produced high-affinity ligands that are 
very selective to their target of interest.  This methodology has an incredibly high success rate 
that is only getting better as the process continues to grow and develop. 
 
2.4 Conclusions 
Over the past ten years in which the project has been in existence, protein-catalyzed 
capture (PCC) agents have proven to be highly effective detection agents that are incredibly stable 
and easy to synthesize1,2,3,6,10.  These agents can be made almost entirely with robotics for ease of 
scale-up, and the capture agents are highly modular, so the addition of labeling tags is trivial.  The 
exact chemical structures of each of these capture agents are known, eliminating the batch to 
batch variability that is common with antibodies and can cause multiplexed assays to be expensive 
and difficult to produce.  A spin-off company, InDi Molecular, is in place for commercialization of 
these agents.  PCC agents are also completely stable, demonstrating no degradation upon 
incubation with mouse liver enzymes, and full functionality after being stored at 65°C as a powder 
for weeks2, demonstrating their excellence for use in anything from clinical work to detection of 
diseases in third world countries3.  The technology development discussed in this chapter has 
revolutionized how screening for PCC agents occurs, and the robustness of these techniques has 
provided a solid foundation for the rapid discovery of a multitude of additional agents for a wide 
range of purposes 1,2,3,6,10. 
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Development of a PCC Agent Selective for the 
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3.1 Introduction 
3.1.1 The E17K Mutation in the Pleckstrin Homology Domain of Akt1 
Akt1 kinase plays a critical role in the PI3K signaling pathway,1 the activation of which is 
closely linked to tumor development and cancer cell survival2.  The phosphorylation of 
regulatory amino acids (Ser474 and Thr308) on Akt occur through the localization of Akt to the 
cell membrane through its membrane-binding Pleckstrin Homology Domain (PH Domain).  These 
phosphorylations activate the Akt protein, which can then activate many other downstream 
signaling pathways2.  The recently discovered E17K mutation in the PH Domain of Akt1 results in 
an increased affinity for the phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3, or PIP3) 
substrate at the cell membrane (Figure 3-1)3.  This switch from a negatively charged glutamic 
acid to a positively charged lysine amino acid in the PIP3 binding pocket causes this mutant 
protein to have a four times higher affinity for the PIP3 substrate.  This increased affinity causes 
the Akt1 to be bound to the cell membrane, and hence activated four times longer than in 
healthy, wildtype cells.  Consequently, this deregulated recruitment of Akt1 to the cell 
membrane causes constitutive activation of the PI3K pathway, which has been shown to be 
sufficient to induce leukemia in mice3.  The oncogenic properties of the driving E17K single point 
mutation make it a target for specific detection and inhibition.    
 
Figure 3-1: PH Domain Binding Pocket Changes upon E17K Mutation: a.) Interaction between Lys14 and Glu17 in 
binding pocket of wildtype PHD, b.) repellent interaction between Lys14 and Lys17 in the binding pocket of the E17K 
mutant, and c.) new hydrogen bonds to water with the E17K mutation in complex with the PIP3 substrate.3  
  53 
3.1.2 A General Strategy for Targeting Single Amino Acid Point Mutations in 
Proteins 
Targeting single amino acid point mutations in proteins is becoming a necessary step in 
the era of personalized medicine, and methods for the detection of these mutant protein 
biomarkers are highly desirable for guiding treatment decisions4.  Thus, there is a need for an 
approach to identify small molecules that can be generally targeted against epitopes containing 
single amino acid point mutations, and can also potentially be developed into cell-penetrant 
inhibitors.  Previously, a strategy was developed for targeting the phospho-epitopes by chemically 
synthesizing the surrounding chunk of protein and focusing the site of the in situ click screen by 
attaching an azide click handle to a phosphate chelating group.5  This method has been 
generalized by directly substituting an alkyne click handle into the chemically synthesized peptide 
epitope.  For this work, the peptide represents the epitope of Akt1 containing the E17K mutation, 
an attractive target due to the oncogenic nature of this mutation3.  That target is subjected to an 
in situ click screen against an OBOC peptide library of 5-mers (comprehensive in 18 amino acids), 
each terminated in an azide presenting amino acid.   
This generalized technique allows us to focus our PCC agent development to a location 
on the PH Domain that is adjacent to the E17K oncogenic mutation. The approach yielded a 5-mer 
peptide that exhibited a 10:1 selectivity for E17K Akt1 relative to wild-type (WT).  We exploited 
the chemical flexibility and modularity of the PCC agent to append a dye and a cell penetrating 
peptide. The resultant ligand could selectivity image the E17K Akt1 protein in live cells, again with 
high selectivity relative to WT.  The technique for epitope targeting described herein provides a 
general approach for the synthesis of small molecule peptides that are capable of selectively 
distinguishing between WT and mutant proteins in cancer.  These small molecule peptides would 
be useful tools for disease detection assays, as well as provide a path towards the inhibition of 
their target proteins. 
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3.2 Materials and Methods 
3.2.1 Akt1 PH Domain Expressions 
Akt1 Pleckstrin Homology Domain DNA was purchased from DNA2.0, and the codons 
were optimized for expression in E.coli.  The first 124 N-terminal amino acids from full-length Akt1 
were used as the PH Domain DNA, and a 6-his tag separated by a thrombin cleavage site was 
added at the C-terminus of the protein for purification.  In order to make the E17K mutant of the 
PH Domain, the glutamic acid in position 17 was mutated to a lysine via QuikChange (Stratagene), 
following all of the manufacturer’s protocols.  The DNA was synthesized in a pJexpress 414 vector 
containing an ampicillin resistant gene to be expressed in E.coli cells.  Protein expression was 
performed by the Protein Expression Center at Caltech using their standard bacterial expression 
protocol, and purified via Ni-NTA column.  The proteins expressed in this manner were used for 
the pull-down assays confirming the anchor binding via immunoprecipitation assays, and for the 
biligand screens.  These PH Domain proteins were unsuitable for long-term storage under a large 
variety of tested conditions, so a GST tag was added to hopefully improve the long term stability.   
For that reason, the DNA from DNA 2.0 was amplified out of the pJExpress vector using 
polymerase chain reaction (PCR) to insert the restriction enzyme sites EcoRI and NotI for insertion 
into a pGEX-4T-1 vector containing a GST tag. The primers used were: 
 5’ - AGAGAATCCATGTCCGACGTCGCGATCGTAAAGGAAGGG – 3’ 
5’ - TCTGCGGCCGCTTAGTGGTGATGATG – 3’   
Both the wildtype and E17K mutant DNA were amplified out of the pJExpress vector, 
restriction enzyme digested, and ligated overnight into a pGEX-4T-1 vector that attached an N-
terminal GST tag to the PH Domain protein.  BL21-DE3-pLys cells were transformed with the DNA, 
confirmed correct via sequencing.  An overnight starter colony from each protein was grown in 
5mL LB + 100 μg/mL Amp overnight.  4mL of this starter culture was used to inoculate 500mL of 
LB+Amp, and grown to mid-log phase.  The cultures were inoculated with 1mM IPTG and grown 
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5 hours at 28°C.  The cells were spun down for 10 minutes at 8,000 RPM and lysed with lysis buffer 
(1x TBS, 1mM DTT, 1mg/mL Lysozyme, 1% Triton-X), and left for 30 minutes on ice before flash 
freezing in liquid nitrogen.  Upon thawing on ice, the lysate was sonicated for 5 minutes, then 
centrifuged for 30 minutes at 10,000 RPM to remove cellular debris.  The supernatant was then 
purified on a HisPur Co column (Pierce) using the recommended protocol.  These GST-tagged 
proteins were used to confirm the biligand binding via immunoprecipitation assays, and for the 
triligand screens.  They were also used to obtain the full ELISA curves of all three ligands.  These 
proteins, however, were also not suitable for long term storage and needed to be re-expressed 
for all assays.   
The imaging experiments required that the PH Domain protein be expressed in 
mammalian cells and have a GFP tag for visualization.  Because of this, Akt1 DNA with codons 
optimized for use in mammalian cells was obtained from InvivoGen as a pUNO-hAKT1 plasmid.  
The DNA was mutated via QuikChange as before so that both a wildtype and E17K version were 
on hand.  The primers used to clone the DNA from this vector into a TOPO C-terminal GFP 
mammalian vector (Life Technologies) were:  
5’ – AAGATGGGGATGAGCGACGTGGCT – 3’ 
5’ – TCCCCGACCGGAAGTCCATCTCCTC – 3’ 
Cloning into the TOPO vector was performed by following all of the manufacturer’s 
recommended instructions.  Because the GST-PH Domain proteins expressed in E.coli were still 
not stable for long term storage, this DNA was used to express the PH Domain in mammalian cells 
to test the storage suitability of this recombinant fusion protein.  The expressions were performed 
by transfecting a suspension culture of HEK-293-6E cells with XtremeGene HD by the Protein 
Expression Center at Caltech following their standard protocols.  These proteins were not purified, 
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and were used as-is out of cell lysates.  This protein was used in triligand pull-down and inhibition 
assays, and was still not stable for long term storage.   
 
3.2.2 Design and Synthesis of Epitope-Targeting Anchor/Target Peptide 
Epitope targeting for the point mutation of the PH Domain of Akt1 was accomplished by 
screening against a 33-mer peptide fragment derived from the N-terminus of the PH Domain, 
highlighted in Figure 3-6, that contained the E17K point mutation as well as a propargylglycine 
(Pra) alkyne click-handle substitution (I19[Pra]) for directing the in situ click reaction near the 
mutated site.  The peptide fragment epitope sequence used in these studies was: 
 MSDVAIVKEGWLKKRGKY[Pra]KTWRPRYFLLKNDG 
This 33-mer fragment was capped with an N-terminal biotin label for detection in the 
screen, and was purified on a prep-scale Dionex U3000 HPLC with a reverse-phase C4 column 
(Phenomenex).  MALTI-TOF MS showed a peak for m/z = 4215.93 for the pure product, expected 
m/z = 4219.9. 
 
3.2.3 CD Spectroscopy of 33-mer Target Peptide Epitope 
Lyophilized powder of the 33-mer biotin-tagged target fragment that was used for 
screening was dissolved in 500μL of 1x PBS to a concentration of 0.5mg/mL.  Concentrations were 
estimated by weight, and confirmed by A280 measurement on a NanoDrop.  Experiments were 
performed using an Aviv 62 CD Spectrometer.  The machine was purged for 20 minutes with N2; 
then, the 1xPBS blank in a 500μL 1cm cuvette was added, and the machine was purged with N2 
for another five minutes.  The spectra was acquired by taking three measurements/minute from 
wavelengths 199-250nM.  The 33mer fragment sample was then added, purged for 5 minutes, 
and was measured exactly as the blank.  The 33mer cuvette was then removed, and 500μL of 
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7.0M Guanadine-HCl (pH = 2.0) was added to denature the sample.  This spectra was acquired as 
above. 
 To work up the data, the signal in ΔA from the sample was subtracted from the blank at 
each wavelength.  Then the mean residue molar circular dichroism ΔεMR was calculated from this 
readout using the number of residues in the fragment (33) and the concentration in mg/mL (0.5 
for the folded sample, or 0.25 for the denatured sample, since it was diluted with Guanadine-HCl) 
using the equation: ΔεMR= ΔA/((residue # x concentration mg/mL) x l)6.  The spectra were 
graphed by plotting this number against the wavelength. 
   
3.2.4 Screen for Initial Anchor Ligand Peptide 
 Screens were performed using a library containing 100% Met coupled at the C-terminus 
for potential MALDI TOF/TOF sequencing7.  The peptide library was a comprehensive 5-mer 
containing 18 unnatural D-amino acids, excluding Met and Cys due to stability reasons.  The N-
terminus consisted of an azide click handle with varying carbon chain lengths – 2 carbon, 4 carbon 
and 8 carbon – for in vivo click with the Pra on the target 33-mer epitope fragment.  Screens were 
completed using with 300mg of dried library beads swelled at least six hours in 1x TBS (25mM 
Tris-Cl, 150mM NaCl, 10mM MgCl2, pH = 7.5) buffer. 
 
Preclear (Figure 3-2a): 
 Swelled library beads were blocked overnight in 5% w/v dried non-fat milk in 1x TBS, then 
washed with 1x TBS three times.  Five milliliters of a 1:10,000 dilution of streptavidin-alkaline 
phosphatase conjugate in 0.5% milk in TBS was added to the beads, and incubated shaking at 
room temperature for one hour.  The beads were washed with a high-salt TBS buffer (1x TBS with 
750mM NaCl) three times, then let shake in high salt buffer for one hour.  The beads were then 
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washed three times with BCIP buffer (100mM Tris-Cl, 150mM NaCl, 1mM MgCl2, pH = 9.0) and 
developed by adding 15mL BCIP buffer plus 13μL BCIP and 26μL NBT (Two part system, Promega).  
After one hour, the purple beads were removed by pipette and discarded.  The remaining library 
beads were incubated in NMP for four hours to remove trace purple precipitate from the 
BCIP/NBT reaction, then were washed five times with methanol, five times with water, five times 
with TBS and blocked overnight in 5% milk. 
 
Product Screen (Figure 3-2b):  
 Beads remaining from the preclear were washed three times with 1x TBS, then incubated 
with 5 mL of a 100 nM dilution of the 33-mer epitope target in 0.5% milk for either 5 hours or 12 
hours to allow for an in situ click reaction to occur.  The beads were then washed three times with 
1x TBS, and incubated for one hour with a 7M Guanadine-HCl buffer (pH = 2.0) to remove all of 
the 33-mer epitope target that was not attached covalently to the beads.  These beads were then 
washed ten times with 1x TBS, blocked for two hours in 5% milk, then incubated for one hour with 
a 1:10,000 dilution of streptavidin- alkaline phosphatase conjugate in 0.5% milk in TBS to detect 
for the presence of the 33-mer epitope target clicked to a bead.  The beads were washed three 
times with a high-salt TBS buffer, then let shake in high salt buffer for one hour.  Afterwards, the 
beads were again washed three times in BCIP buffer, and developed as per the preclear.  Purple 
beads are removed from the screen via pipette, and are considered hit beads.  These hits were 
incubated in the guanidine-HCl buffer to remove attached streptavidin, washed ten times with 
water, and sequenced via Edman degradation on a Procise CLC 494 system from Applied 
Biosystems.  See Table 3-2 for the 5-hour sequences and Table 3-3 for the 16 hour, overnight 
sequences. 
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3.2.5 Hit Library Bead Sequence Analysis 
Hit sequences were segregated based on their hydrophobicity and sequence homology 
using principal component analysis.  The algorithm analyzes a series of peptides via 
hydrophobicity and sequence homology, and graphs them on a 2D sequence map (Figure 3-7).  
Clusters of hits were circled, and one peptide from each cluster was scaled-up and tested for 
binding to both wildtype and E17K mutant PH domain.  The ligands chosen for scale-up were: 
dqntr, ypwve, eefef, yleaf, and elnhy.  Any ligand candidates that were difficult to call on the 
sequencing were not chosen for scale-up and testing. 
  
3.2.6 Streptavidin-Agarose Immunoprecipitation (Pull-down) Assays for Binding 
Affinity 
Pull-down assays were done on streptavidin agarose resin (Invitrogen).  The resin was 
incubated with N-terminal biotinylated anchor peptide candidates identified via the principle 
component analysis seen in Figure 3-7.  The anchor candidate-coated beads were then incubated 
with both wildtype and E17K mutant protein to compare the selectivity of the ligands as well as 
the binding ability. 
 
Figure 3-2: Screening Strategy for Anchor Ligand Determination (a) Preclear: Library beads are incubated with 
streptavidin - alkaline phosphatase conjugate to remove any library beads that bind to this or the BCIP reagents. (b) 
Product Screen: Precleared library beads are incubated with the 33-mer target peptide containing an azide in situ click 
handle.  The fragment catalyzes triazole formation between the alkyne on the 33-mer target and the azide on beads 
that contain peptide sequences that bind specifically to the 33-mer in a close enough proximity to the alkyne substitution 
for a click reaction to occur without copper.  The unclicked peptide is then stripped from the beads, and the remaining 
covalently attached 33-mer is detected by streptavidin – alkaline phosphatase with BCIP development. 
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Assays were performed using 50μL of streptavidin-agarose slurry (25μL resin) in Spin-X 
tubes (Sigma) to allow for the easy removal of the solutions.  Resin was aliquotted into 14 tubes 
– six ligands plus a blank tested against two different proteins – then washed three times with 1x 
TBST (1x TBS + 0.1% Tween-20).  Each set of tubes was incubated with a 10x excess of the 
appropriate biotinylated ligand to streptavidin binding sites in 200 μL 1x TBS or plain buffer for 
the blank.  Ligand binding was done for one hour at room temperature, and then resin was 
washed three times with 1x TBS.  Resin was blocked with 1x TBS with 5% BSA for two hours.  The 
anchor-coated resin was then incubated with either wildtype or mutant expressed PH domain 
protein overnight (~16 hours) in cold room (4°C).  Protein was spun out of tubes, and the resin 
was washed three times with high salt TBS, then incubated for five minutes in the high salt buffer.  
The resin was then washed three times with the 1x TBS buffer, and spun out to dry completely.  
Fifty μL of denaturing SDS gel loading buffer with 10% B-mercaptoethanol was added to the 
sample,s and they were incubated at 95° C for ten minutes to denature from the resin.  The gel 
loading buffer was spun out of the Spin-X tubes, and the samples were run on an Any KD BioRad 
Premade Gel under denaturing conditions.  Gel was transferred to nitrocellulose membrane, 
blocked for one hour in 5% milk (4°C), and western blotted8.  Proteins were detected using rabbit 
polyclonal anti-Akt1 antibody (ab64148, Abcam) and an anti-rabbit HRP conjugated secondary 
anti-body (Cell Signaling), then developed with West Pico Chemilluminescent substrate (Pierce).  
Relative protein band sizes were analyzed to compare binding between the anchor candidates, 
and were used to determine selectivity for either wildtype or mutant PH Domain.   
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3.2.7 Point ELISAs with Anchor Ligand and 33-mer Epitope (Epitope Targeting 
Verification) 
The 33-mer epitope used in screening was resynthesized without the alkyne click handle 
and with a 6-His tag as an orthogonal tag to the biotin on the anchor ligand.  This tag was added 
after a PEG5 on the N-terminus of the peptide, and was made and purified as was previously 
described.  The mutant fragment had an expected m/z of 5160.72, observed MALDI-TOF MS m/z 
for [M+H] of 5161.61.  The WT fragment has an expected m/z of 5161.72, and an observed MALDI-
TOF MS for [M+H] of 5162.78.  
 For these assays, 100nM Biotin-
PEG5-yleaf-Pra (Figure 3-3) was 
immobilized for one hour on a 
Neutravidin-coated ELISA plate 
(Pierce).  The plate was blocked in 
5% BSA in 1xTBS for one hour, then again overnight at room temperature.  The immobilized 
anchor was then incubated with either 1μM or 100nM wildtype 33-mer epitope or 1μM or 100nM 
E17K mutant 33-mer epitope for one hour.  The plate was washed three times with 1xTBS + 0.1% 
Tween-20, and tapped dry.  The epitope was then detected by a 1:1,000 dilution of an anti-his 
mouse mAb (ab18184, Abcam) for one hour, washed as above, and then detected with 1:10,000 
dilution of an anti-mouse HRP-conjugated goat pAb (Abcam) for one hour.  The plate was once 
again washed and developed with a 1:1 TMB substrate (KPL) for 15 minutes.  To graph the data, 
the blank (epitope and antibodies binding to plate with no anchor ligand present) was subtracted 
from the triplicate sample values.  The fraction bound was found by setting the highest value to 
100% and normalizing the rest accordingly.  The triplicate values were then graphed with their 
error bars, and the p-values were calculated by GraphPad using a two-way ANOVA test. 
 
Figure 3-3: Biotin – PEG5 – yleaf – Pra Anchor ligand:  As analyzed by 
MALDI-TOF MS, expected m/z = 1298.62, observed [M+Na] = 1319.89. 
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3.2.8 HPLC-Detected Immunoprecipitation (Pull-down) Assays (Epitope Targeting 
Verification) 
Pull-down assays with the biotinylated anchor and his-tagged 33-mer epitope were 
performed to verify epitope targeting.  As with the full-protein assays, the biotinylated anchor 
ligand was incubated for one hour with 50μL of streptavidin agarose slurry that had been washed 
three times with 1xTBS.  The anchor ligand was washed out, and the resin was blocked for an hour 
in 5% BSA in 1xTBS.  Two hundred μL of a 50μM solution of his-tagged 33-mer epitope in 1xTBS 
was added to the blocked resin, and this was incubated overnight (~16 hours) at 4°C.  Because 
small peptide fragments like the 33-mer epitope are difficult to transfer to and detect on the 
nitrocellulose membrane as for a traditional Western blot, the amount of binding in these assays 
was detected via HPLC.  In order to do this, the bound 33-mer peptide fragments were washed 
three times with 1xTBS + 0.5% BSA, and one time with 1xTBS.  The resin was then incubated with 
200μL of the 7M guanadine-HCl (pH = 2.0) buffer used to strip beads in the screen.  The guanidine 
buffer was spun out of the beads in Spin-X tubes and injected onto a Beckman Coulter semi-prep 
HPLC with a reverse phase C18 analytical column.  The peak seen on the HPLC illustrated how 
much of the 33-mer epitope bound to either the yleaf anchor or to blank beads. 
 
3.2.9 Ligand-Directed Tosyl Labeling Experiments 
For these assays, the yleaf anchor was appended with an N-terminal FMOC-piperidine-4-
carboxylic acid (pip) as a linker on 300mg of rink amide resin in NMP using standard FMOC amino 
acid coupling techniques.  The resin was equilibrated in anhydrous DCM, and 250μL of 3-
(chlorosulfonyl)benzylchloride (tosyl) was added with 450μL of DIEA and shaken for 30 minutes 
at room temperature.  Then, 250μL of 2-(2-(2-aminoethoxy)ethoxy)ethanol (EG), 450μL of DIEA 
and 19mg DMAP in anhydrous DMC were added and shaken overnight.  The resin was washed 
and equilibrated in NMP, and 2eq Cy5 carboxylic acid (Lumiprobe) was coupled at 37°C overnight 
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using standard FMOC coupling techniques.  The resin was washed, TFA cleaved and HPLC purified 
as usual; see Figure 3-4 for image. 
 In order to label the 
protein, 50μL of full-length 
GST-E17K PH Domain from 
SignalChem was treated 
with 10x molar excess of the 
anchor ligand with the 
tosylate dye label and 
incubated for two days at 
room temperature.  The 
mixture was lyophilized 
after two days, and then denatured by boiling in SDS-PAGE loading buffer.  The labeled protein 
was run alongside an unlabeled control on an Any-KD gel (Biorad), then imaged on an Odyssey 
fluorescent gel reader (Figure 3-13).  After confirming that labeling had occurred, the gel was 
stained with BioSafe Coomassie blue stain (BioRad), and the blue protein bands were cut out.  The 
gel pieces were trypsin digested using the Pierce In-gel Digest Kit, following all of the 
manufacturer’s instructions.  The tryptic fragments from both the unlabeled and labeled protein 
digests were lyophilized to concentrate them, taken up in 2μL of 50% H2O/50% Acetonitrile, and 
were analyzed by MALDI TOF MS. 
 Initially, analyses were performed by considering any peak that was present in the labeled 
protein sample that was not present in the unlabeled sample.  The weight of the dye labeling arm 
– 552.3 g/mol – was subtracted from these peaks, and the corresponding tryptic fragment was 
located.  This provided four potential fragment candidates that were all located near the 33-mer 
 
Figure 3-4: TAT – PEG5 – yleaf – pip- tosyl – EG – Cy5: Labeling experiments were 
performed using a yleaf anchor ligand (blue) that was built onto a TAT peptide 
(red) with a PEG spacer (black).  The labeling arm consisted of a pip spacer, tosyl 
labeling group, and EG spacer (green) with a Cy5 dye (pink) payload. MALDI-TOF 
MS, expected m/z = 3316, observed m/z [M+H} = 3317.50. 
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epitope in the PH domain of the protein.  Next, every MALDI peak in the labeled sample was 
analyzed by subtracting the weight of the dye label and comparing it to a potential tryptic 
fragment.  One other fragment was identified using this method, and corresponded to the doubly 
labeled peak of one of the previously identified labeled fragments.  These results confirmed 
multiple previous experiments done using LC/MS techniques that proved not strong enough to 
fragment the tryptic peptides into individual amino acids. 
 These tryptic peptide samples were then analyzed by MALDI TOF/TOF MS to identify the 
exact amino acid that contained the dye label.  Only YFLLK was able to be successfully fragmented, 
and the TOF/TOF confirmed that the tyrosine was the label-containing amino acid.  This confirms 
the results, seen in the original publication,9 that only Y, H, and E nucleophilic amino acids are 
labeled using this technique.  The remaining tryptic fragments all contain at least one of these 
amino acids, with the doubly-labeled fragment containing two. 
 The labeling sites were then plotted onto a Pymol image that combined the Akt1 protein 
(PDB ID: 3096) and the E17K PH Domain (PDB ID: 2UZR) with the N-terminal GST tag (PDB ID: 
1UA5) that was present on the full-length protein from SignalChem that was used in these labeling 
assays.  This Pymol-made fusion protein was used to approximate what the commercial protein 
looked like in solution and give an idea of the extent of the selectivity of this assay.  The 
concentration of labeling sites only surrounding the epitope demonstrate the exclusive binding of 
this ligand in solution.  
 
3.2.10 Details of the MALDI-TOF Analysis of Tryptic Peptide Fragments 
All of the peaks from the MALDI-TOF spectra of the labeled tryptic digests were analyzed 
for their potential to contain a dye label.  The MALDI spectra were manually calibrated to ensure 
the least possible error.  Each peak was then analyzed by zooming in on the spectra on the 
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computer and obtaining the exact mass for the monoisotopic peak, which is recorded as “MALDI 
peak” in Table 3-1 below.  The mass of the dye, 552.37g/mol, was subtracted from this peak, and 
it was compared to the closest possible theoretical tryptic digest fragment (“Digest”).  The 
“expected” mass of the digest plus the dye was calculated and subtracted from the observed 
mass, “MALDI peak,” and the absolute value of this difference was recorded in “P/M 1.”  The peak 
area was obtained from the MALDI data and added to the spreadsheet as “Peak Area” to allow 
for a cutoff (4500) of any peaks that looked to be within the noise.  Any peak below this value is 
shown in red italics, and was not considered for this study.  Any peak that was within 0.1% of the 
mass of the expected digest mass was considered to be within error of the instrument, was 
considered a hit dye-labeled fragment, and colored blue in the table.  There were no more new 
peaks seen using this method than were discovered by looking for peaks that grew in from the 
unlabeled MALDI to the labeled MALDI.  The labeled sites seen in this MALDI-TOF experiment 
were all seen previously in at least 2 LC/ESI-MS experiments attempting to identify the labeled 
region. 
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dye Expected Digest 
Peak 
Area P/M 1 
Corresponding 
Fragment 
1053.15 500.78 1051.6349 499.265 4296.69 1.5151  
1090.15 537.78 1114.6007 562.2307 5813.86 24.4507  
1118.11 565.74 1114.6007 562.2307 12649.91 3.5093  
1142.16 589.79 1132.6993 580.329 4217.63 9.4607  
1179.14 626.77 1173.6565 621.287 4393.2 5.4835  
1194.14 641.77 1201.732 649.362 5139.51 7.592  
1202.16 649.79 1201.732 649.362 4103.69 0.428  
1234.66 682.29 1234.7826 682.4126 8193.47 0.1226 YFLLK 
1300.08 747.71 1303.7273 751.3573 6445.8 3.6473  
1302.09 749.72 1303.7273 751.357 4496.81 1.6373  
1308.09 755.72 1303.7525 751.3825 5926.62 4.3375  
1320.57 768.2 1320.7691 768.3991 7886.31 0.1991 EGWLHK 
1440.11 887.74 1447.8246 895.4546 6406.74 7.7146  
1475.16 922.79 1477.9158 925.5458 10131.17 2.7558  
1493.13 940.76 1477.9158 925.5458 9276.21 15.2142  
1499.13 946.76 1507.814 955.444 4112.05 8.684  
1515.1 962.73 1507.814 955.444 4687.71 7.286  
1567.65 1015.28 1565.8591 1013.489 7907.73 1.7909  
1639.2 1086.83 1645.9403 1093.57 21961.13 6.7403  
1707.53 1155.16 1701.0101 1148.64 12923.9 6.5199  
1791.09 1238.72 1795.9606 1243.591 5200.25 4.8706  
1802.79 1250.42 1800.0105 1247.641 8149.76 2.7795  
1851.79 1299.42 1841.9813 1289.61 4331.77 9.8087  
1995.47 1443.1 1957.1459 1404.78 4368.22 38.3241  
2212.04 1659.67 2213.208 1660.838 95735.94 1.168 EEWTTAIQTVADGLK 
2225.51 1673.14 2213.208 1660.838 17712.89 12.302  
2233.95 1681.58 2213.208 1660.838 12256.12 20.742  
2284.12 1731.75 2344.242 1791.872 5711.7 60.122  
2306.92 1754.55 2344.242 1791.872 6553.24 37.322  
2344.23 1791.86 2344.242 1791.872 4506.1 0.012 EAPLNNFSVAQCQLMK 
2383.46 1831.09 2362.2571 1809.887 8608.79 21.2029  
2406.7 1854.33 2362.2571 1809.89 4338.6 44.4429  
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The peak at ~2212 was not seen on the unlabeled mass spec, but is seen on the labeled 
fragment, and was considered a hit.  The peak at 2211 is also, however, a common mass seen for 
trypsin.  We do see this particular unlabeled fragment fly in the MALDI-TOF MS (1659), and know 
that this is a site that can be labeled, based on the ESI-MS experiments that were conducted with 
a biotin and not Cy5 labeling arm (which therefore have a different labeled mass) that this is a site 
that can be labeled.  In attempting to zoom in for the monoisotopic mass, we see a broad peak 
with no clearly-identifiable mass peak – unlike all of the other peaks in the spectrum, which 
showed the distribution of masses very clearly.  This led us to believe that we are, in fact, seeing 
this peak labeled in the MALDI, especially since this site was seen as labeled by the ESI, and that 
the MALDI spectra is showing an overlap of the trypsin peak with the labeled fragment.  The ESI 
labeling experiments were done using the biotin labeling arm, so this mass did not overlap with 
trypsin in these experiments, which confirms this.  We just cannot exactly call this mass in the 
MALDI due to the similarity of this peak to that of trypsin. 
 
3.2.11 Images of Anchor Ligand in HEK-293T Cells Expressing PH Domains 
 
These experiments were designed to visualize the dye-labeled anchor ligand in cells 
overlapping with the GFP-labeled PH Domain proteins.  For this reason, the yleaf anchor ligand 
was synthesized with an N-terminal PEG5, TAT (YGRKKRRQRR), and Cy5 dye (Figure 3-5).  GFP-
 
Figure 3-5: yleaf – PEG5 – TAT – Cy5: The yleaf anchor ligand (red) was appended with a TAT cell penetrating 
peptide (blue) and a Cy5 dye (pink) separated by a PEG5 linker (black). MALDI-TOF MS, expected m/z: 2937.72, 
observed m/z = 2937.83. 
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tagged protein DNA was also cloned as described above.  HEK-293T cells were grown in DMEM 
media supplemented with 10% FBS (both Invitrogen), 100x non-essential amino acid solution 
(Sigma), and PenStrep antibiotic (Invitrogen).  Once the cells reached ~80% confluency, they were 
treated with trypsin to remove from the plate and split into a 12-well flat bottom cell culture plate 
with a D-poly-lysine (BD) coverslip at approximately a 50% confluency in 1mL total volume.  The 
cells were allowed to attach to the coverslips for approximately 24 hours, then were transfected 
to express either wildtype GFP-PH domain or E17K mutant GFP-PH domain proteins using 
XtremeGene HD transfection agent at a ratio of 3:1 transfection agent to DNA.  Several wells were 
left untreated as no protein blanks.  The cells were given 24 hours to express protein.  They were 
then serum starved for one hour in DMEM media prepared as above, but without the FBS.  After 
one hour, the Cy5-labeled anchor was added to the wells to a final concentration of 50nM.  As the 
HEK-293T cells express endogenous Akt1 protein, this level was adjusted to give the lowest 
background signal possible.  The protein blank cells were also incubated with 50nM of the yleaf 
anchor to ensure that binding was due to the presence of the E17K mutant protein.  A blank of 
PEG5-TAT-Cy5 was also added to wells expressing either wildtype or E17K mutant to ensure that 
ligand binding was due to the presence of the yleaf anchor.  After a one-hour incubation with the 
peptide, the cells were washed once in serum starved media, then incubated thirty minutes in 
serum starved media to wash out any excess peptide.  During this time, the cells were also treated 
with 10μg of Hoescht 33342 dye to stain the nuclei.  After the thirty-minute period, one well of 
each wildtype or mutant protein with peptide was activated with PDGF for 10 minutes.  The cells 
were then washed twice with cold PBS buffer, fixed with 10% Neutral Buffered Formalin Solution 
(Sigma) and glued onto microscope slides.  Images were taken on a Zeiss LSM 510 Meta NLO with 
Coherent Chameleon confocal microscope.  A 40x Plan-apochromat lens was used.  The laser 
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intensity and gain were fixed for all pairs of images between wildtype and mutant samples to 
ensure that the differences seen were not artificially created. 
 
3.3 Results and Discussion 
3.3.1 In situ Click Epitope-Targeted Screening Strategy for E17K PH Domain-
Specific Ligand 
Using FMOC SPPS peptide synthesis techniques,10 a peptide epitope representing 
residues 1-32 of the E17K PH Domain of Akt1 was synthesized.  From the crystal structure (PDB 
ID: 2UZR), these residues form a β-sheet around the E17K mutation (blue).  The epitope fragment 
was appended with an N-terminal PEG5-biotin to serve as a detection handle when screening.  
This manual synthesis of the epitope allowed for an I19Pra substitution (Pra – propargylglycine) 
to provide an alkyne click handle on the most proximal side-chain residue to the E17K mutation.  
Following chromatographic 
purification, and 
characterization via mass 
spectrometry, HPLC and circular 
dichroism, the modified epitope 
was ready for screening.  
A single generation in 
situ click screen can yield ligands 
with a high selectivity for the 
target.  Hits from such a screen 
are those library elements that 
are covalently coupled to the synthetic epitope through a triazole linkage.  The in situ click 
reaction itself is low yielding12, but the biotin handle on the synthetic epitope permits enzymatic 
 
Figure 3-6: Design of Screening Target Epitope: PH Domain (green) with 
highlighted screening target epitope (pink).  The epitope was designed to 
surround the E17K mutation shown in blue.  The amino acid in position 19 was 
substituted with a propargylglycine (Pra) alkyne-containing amino acid 
(yellow) for focusing the site of the in situ click screen. 
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amplification of those hit beads using a colorimetric streptavidin-linked alkaline phosphatase 
assay.  The basic screening strategy is shown in Figure 3-2. Out of the 1.5 million library members 
that were screened against the alkyne-containing 33-mer E17K PH Domain fragment, only 21 
beads (0.0014%) showed the presence of the covalently coupled epitope.  These beads were 
sequenced using Edman degradation ( 
Table 3-2, Table 3-3).  The hits were segregated based on their hydrophobicity and 
sequence homology using principal component analysis (Figure 3-7).  Based upon this analysis, 
five ligands that represented the diversity of hits (circled in Figure 3-7) were scaled-up with a 
biotin tag and tested for binding to both E17K and WT full-length PH Domain.  These hits were 
dqntr, ypwve, eefef, yleaf, and elnhy.  Here, the lowercase sequence letters indicate that the 
amino acids that comprise the peptide are non-natural D-stereoisomers. 
 
Table 3-2: Hit Sequences from Anchor Screen against 33-mer peptide epitope (5hr click screen): 
Az2 G v e k f 
Az8 y h e w f 
Az4 i s e y e 
Az2 p h w l/k f 
Az8 d l l t f 
Az4 a r s d f 
Az8 f k/l  G t 
Az8 f e i q  
Az8 e e p d/n f 
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Table 3-3: Hit sequences from Anchor screen against 33-mer peptide fragment (16hr screen): 
Az4 e e f e f 
Az8 f e e a i 
Az2 e l n h y 
Az2 h a r h q 
Az2 h e w v t 
Az4 n w y a w 
Az4 n l v p n 
Az2  r r r f 
Az4 a l n s k 
Az8 p  a y h 
Az2 n r y v r 
Az8 y l e a f 
 
 
Streptavidin – agarose immunoprecipitation assays (Figure 3-8) were used to probe for 
the ability of the anchor candidates to recognize and bind to the proteins in buffer. One ligand 
 
Figure 3-7: Clustering of Anchor Sequence Ligands by AA Similarity: Hit sequences from the anchor screen were 
segregated based on their hydrophobicity and sequence homology using principal component analysis.  Circled clusters 
indicate regions where a peptide was selected and scaled-up as a possible anchor sequence.  The potential anchor 
sequences that were tested are: dqntr, ypwve, eefef, yleaf and elnhy. 
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candidate showed a distinctively stronger binding to the E17K protein relative to the WT, seen in 
Lane 5.  This peptide sequence, “yleaf,” (Figure 3-3) was carried forward for additional 
investigations.  Two out of the four other candidates, though, also showed a preference for the 
E17K mutant protein.  One candidate showed a preference for the WT protein, and one candidate 
showed no strong binding to either fragment.  This result was to be expected, because it is 
possible for a ligand to bind to the fragment in a way that is not directly accessible on the surface 
of the full protein.  It can also be hypothesized that the three fragments that showed a preference 
for the E17K fragment bound at or around the site of the mutation, and the peptide that shows 











3.3.2 CD Spectroscopy of 33-mer Target Peptide Epitope 
In order to determine whether the epitope used in the screen would retain the 
secondary structure of the full protein, CD spectroscopy was performed (Figure 3-9).  The biotin-
tagged, alkyne-containing fragment that was used as a screening target was tested, and the 
resultant spectra do show the presence of secondary structure.  This result is confirmed by the 
 
Figure 3-8: Streptavidin-Agarose Pull-down Assays for Anchor Ligand Binding Affinity: 
Streptavidin-agarose was incubated with a panel of potential anchor sequences that were 
synthesized with biotin tags.  These resins were then incubated with either wildtype or E17K 
Mutant PH Domain to measure the amount of protein that is pulled down by each potential 
anchor ligand. 
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disappearance of this structural signature upon the addition of a denaturing guanidine-HCl 
buffer.  More importantly, the characteristic dip at 217nM of the blue, fully-natured fragment 
spectra is the signature of a β-sheet, which is the expected structure of this part of the full 
protein.  We can assume, then, that this fragment is maintaining a structure similar to that of 
the natured protein, even with the incorporation of the click handle.  Therefore, peptide binding 
to the E17K fragment should see a surface similar to that of the full-length PH Domain protein.  
The messiness of the spectra from 200 – 210 nm could be due to the biotin label that has been 
attached to the fragment, or be due to the absence of the rest of the protein, causing random 
coiling or unfolding. 
 
3.3.3 Verification of the Epitope Targeting Strategy 
The biotin-modified yleaf peptide (Figure 3-3) was subjected to a variety of binding assays 
against the synthesized WT and E17K 33-mer PH Domain fragments prepared without the biotin 
label and alkyne click handle.  These assays were instead labeled with an N-terminal 6-His tag in 
 
Figure 3-9: CD Spectra of 33mer Epitope Fragment used in Screening: The blue spectra indicates the 33mer target 
fragment that was used in screening; the red indicates the denatured epitope. 
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order to have an alternative detection handle to the anchor ligand.  First, the yleaf peptide was 
used in immunoprecipitation assays to pull-down either the WT or E17K mutant 6His-tagged 33-
mer peptide fragments, as opposed to the full-length proteins that were used to initially validate 
the candidates.  Typical immunoprecipitation assays involve western blotting to estimate the 
amount of protein binding, but peptide fragments are too small to be consistently captured or 
quantified on a blot.  Because of this, the amount of peptide epitope precipitated in these assays 
was quantified via injection onto an analytical HPLC.  These unique immunoprecipitation assays 
further confirmed preferential yleaf ligand binding to the E17K mutation relative to the WT 
epitope (Figure 3-10).  As an assay control, another candidate ligand that, in initial testing, did not 
exhibit preferential E17K binding to the full protein (lane 4, Figure 3-8), was tested, and yielded 
consistent results to the full-protein pull-down assays (Figure 3-8).  The first immunoprecipitation 
assays demonstrated that the anchor bound selectively to the full-protein, and these HPLC-
detected pull-downs confirm that the binding and the selectivity are due to the interaction 
between the anchor and 33-mer epitope. 
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 The selectivity of the yleaf peptide for the E17K 33-mer epitope was also tested in an 
ELISA assay format.  For these assays, the WT or E17K 33-mer peptide fragments were captured 
using the PEG-biotin-modified yleaf ligand 
immobilized on a Neutravidin-coated plate.  The 
yleaf ligand exhibited significant selectivity for 
the E17K fragment over the WT across a 100 nM 
– 1 μM concentration range (Figure 3-11), 
further demonstrating the binding of this ligand 
to the specific epitope of interest and providing 





Figure 3-10: HPLC-detected Immunoprecipitation Assay for Epitope Targeting Verification. The HPLC traces show 
the quantity of the 33-mer fragment that was pulled-down in the assay.  The anchor ligand, yleaf, pulls down the 
most E17K 33-me,r and the least WT 33-mer.  The amount of pull-down by the eefef discarded anchor candidate 
demonstrates the validity of the assay.  This corroborates what was seen in the full-protein pull-downs in Figure 
3-8. 
 
Figure 3-11: ELISA Assay Verification of Epitope Targeting. 
The WT and E17K 33-mer fragments were incubated with 
the yleaf anchor immobilized on an ELISA plate.  Strong 

























― yleaf, E17K 33mer 
― eefef, E17K 33mer 
― yleaf, WT 33mer 
― blank, E17K 33mer 
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3.3.4 Ligand-Directed Labeling Experiment to Confirm Epitope Targeting and 
Ligand Selectivity 
The selectivity of the yleaf anchor ligand 
was further verified using the directed labeling 
technique reported by Tsukiji et al9.  The 
approach yields information relative to the 
binding location of the ligand on the protein 
target.  For this method, a payload is attached 
to the N-terminus of the targeting yleaf ligand 
through an electrophilic tosylate linker.  Upon 
ligand binding to the protein target, the payload 
is transferred onto the protein through a nucleophilic SN2 reaction with proximal nucleophilic 
amino acid side chains (Figure 3-12).  The protein can then be trypsin-digested, and the identity 
of the fragments containing the payload can be 
mapped on the protein surface using mass 
spectrometry (MS).  Thus, the site of ligand binding 
can be estimated.  The assay also serves as an 
independent validation of the immunoprecipitation 
and ELISA binding assays discussed above.  
 For the assay, yleaf was modified at the N-
terminus to contain a tosylate linker attached to a 
Cy5 dye molecule to enable easy identification of the 
labeled and digested protein fragments (Figure 3-4).  A Glutathione S-Transferase (GST)-
Akt1(E17K) protein (SignalChem) was incubated with the Cy5-appended yleaf peptide.  The 
labeling of the protein target was initially confirmed by visualization on a fluorescent gel reader 
 
Figure 3-12: Ligand-Directed Labeling Diagram, 
modified from Tsukiji et al9.  The anchor (red) with the 
Cy5 dye (pink) attached through an electrophilic tosyl 
group.  The reaction with nucleophilic side-chains on the 
protein can indicate where the ligand is binding.  These 
sites can be confirmed through trypsin digestion and MS.   
 
Figure 3-13: Fluorescent Gel Image to Confirm Cy5 
Labeling. Lane 1 shows the control protein with no 
label, and Lane 2 shows the labeled protein.  The 
large band corresponds to the labeled GST-E17K-
Akt1. 
1. 2. 
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(Figure 3-13).  The labeled protein and an unlabeled control were then trypsin-digested from the 
gel, and were analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
MS (Figure 3-14).  Five peaks appeared in the MS of the labeled protein that were not present in 
the unlabeled protein digests, which all corresponded to an expected trypsin fragment plus the 
weight of the linker and dye. 
 
These peaks were then analyzed by MALDI TOF/TOF MS to extract sequence information 
for the labeled regions of the protein.  All but one of the dye-labeled peptides were difficult to 
fragment, as is characteristic of cationic peptide labels11.  The labeled digest YFLLK could be 
fragmented, and indicated the presence of the dye on the Y amino acid (Figure 3-15).  This is 
consistent with the original literature on the labeling technique,9 which showed that Y, E and H 
amino acids are the nucleophiles that can be labeled.  The other labeled Akt1 fragments that were 
identified contain at least one of these amino acids.  One fragment contains two such amino acids 
and, in fact, there were MALDI peaks corresponding to the masses of both the singly-and doubly- 
 
Figure 3-14: Images of Labeled and Unlabeled MALDI-TOF Spectra of Unlabeled (top) and Labeled (bottom) Proteins.  
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labeled fragments.  Figure 3-16 shows the location of the labeled fragments in the PH Domain 
sequence, as well as the amino acids that should contain the label.  
 
The labeling sites were then mapped on a composite crystal structure of GST (PDB ID: 
1UA5) and Akt(E17K) (Akt PDB ID: 3096, E17K PDB ID: 2UZR) (Figure 3-17).  All labeled sites 
surround the anticipated binding site of the 
yleaf ligand.  A thorough search of the entire 
MALDI spectra was conducted to identify 
any other labeled fragments anywhere on 
the large protein, but none were found.  
Thus, this labeling experiment demonstrates that only sites around the expected N-terminal 
binding site of the yleaf ligand are labeled, confirming the very specific binding of the peptide 







Figure 3-15: MALDI-TOF/TOF Cy5 Dye-Labeled YFLLK Fragmentation:  The YFLLK – Cy5 Labeled trypsin fragment 
analyzed by MALDI-TOF/TOF MS.  The fragments shown above demonstrate that the Cy5-dye is on the Y amino acid, 
which corresponds to the results found by authors of the original technique9. 
 
Figure 3-16: Trypsin-Digested Sequence of PH Domain 
Protein. The red dashed lines show where the trypsin cuts are 
located.  The fragments highlighted in red are the ones that 
showed labels, and the amino acids colored in cyan are the 
ones containing the labels. 
  79 
 
 
3.3.5 In Cell Imaging 
Live cell-based assays can provide a demanding environment for demonstrating the 
selectivity of the yleaf PCC agent to the E17K Akt1.  In addition, they also can demonstrate the 
value of a small, epitope targeted ligand relative to a similarly targeted antibody, since antibodies 
cannot enter live cells.  To demonstrate target binding in live cells, HEK-293T cells were 
transfected to express GFP-tagged E17K or GFP-tagged WT PH Domain proteins.  The yleaf ligand 
was then labeled with both a Tat cell-penetrating peptide and a Cy5 dye (Figure 3-5).  The 
combination of the GFP label on the protein, and the Cy5 label on the dye, permitted the use of 
multi-color fluorescence microscopy for interrogating any spatial registry between the two 
 
Figure 3-17: Compiled Crystal Structure of Fully Labeled Protein. The cyan amino acids labeled in cyan are all clustered 
immediately around the pink 33-mer fragment of the blue PH Domain.  No labeled sites were found in any other part of 
the large fusion protein. 
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fluorescent labels.   Live HEK-293T cells expressing these GFP-tagged proteins were exposed to 
varying concentrations of the modified yleaf ligand for one hour.  The cells were then thoroughly 
washed with PBS to equilibrate the concentration, and fixed for fluorescence microscopy 
measurements.   
  
Confocal microscopy images of the two differentially-expressing Akt1 PH Domain cells 
showed a consistent level of expression between 
the GFP-WT PH Domain and GFP-E17K PH Domain.  
However, the level of the PCC agent retained by 
the cells was substantially different (Figure 3-18).  
Nearly all of the cells expressing the mutant 
protein show some level of capture agent 
retention and demonstrate co-localization of 
capture agent and GFP-PH Domain protein (Figure 
3-19).  The GFP-WT cells, however, show very low levels of capture agent retention, and do not 
 
Figure 3-18: Images of Anchor Ligand in GFP-tagged WT and E17K PH Domain. The green fluorescence shows the 
equivalent expression of the WT and Mut proteins in cells.  The pink anchor ligand is distributed throughout almost all 
of the E17K – expressing proteins, but shows only background binding to the WT – expressing cells. 
 
Figure 3-19: Image Demonstrating Co-Localization of 
Cy5 - PCC Agent with GFP - tagged PH Domain proteins 
in cells. 
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seem to have any co-localization of the two.  These measurements demonstrate the selectivity of 
the E17K capture agent for its target within the demanding environment of live cells.  
  
3.4 Conclusions 
The in situ click-focused epitope screen for capture agent development presents a rapid 
strategy for discovering peptide ligands that bind to any site of interest on a protein surface.  This 
method is not limited to conserved binding pockets, post-translational modifications, or 
structured regions of proteins.  By only accepting hits wherein the target epitope catalyzed the 
formation of a covalent bond, it was ensured not only that the candidate ligands bound to the site 
of interest, but that they also bound tightly and in an exact orientation so that this triazole could 
form.  In this way, the in situ click screen became not only a screen for ligand affinity, but also for 
ligand specificity.  The peptide hits developed using this method are very specific for the exact 
location on the protein where the click reaction was centered.  The PCC Anchor, yleaf, developed 
using this technique has demonstrated the ability to detect the E17K mutant PH Domain in 
conditions ranging from simple assays in buffer to complex imaging experiments in cells.  Assays 
validating the peptide-peptide binding of the epitope target and the yleaf anchor ligand also 
highlight the exquisite selectivity of this ligand for the E17K mutation.  This technology provides 
an ideal solution for the discovery of selective ligands to an area of interest on a protein surface, 
and demonstrates the ability to produce agents capable of distinguishing even the slightest 
change in protein structure – a single point mutation. 
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4.1 Introduction 
As described in previous chapters, there is increased interest in compounds that can 
selectively inhibit a disease-associated mutant protein target while sparing the wildtype (WT) 
variant1. PHD inhibiting compounds2,3 with selectivity for the E17K variant of Akt have not been 
reported. The specificity of the yleaf anchor ligand described in Chapter 3 for the E17K Akt1 in live 
cells, coupled with the proximity of the E17K mutation to the PIP3 binding site, prompted the 
consideration of further developing this PCC Agent into a compound capable of blocking the E17K 
PH Domain interaction with its PIP3 substrate.  The yleaf anchor peptide itself did not exhibit 
evidence of inhibition (Figure 4-11).  It was reasoned that a similarly targeted, but bulkier PCC 
Agent might serve as a steric blocker of the PH Domain - PIP3 interaction.  To this end, two cycles 
of iterative in situ click chemistry screens, as described in Chapter 2, were executed in order to 
develop the yleaf ligand into a biligand and then a triligand, which was capable of successfully 
blocking this binding interaction.   This showed that these larger PCC Agents could serve as highly 
selective inhibitors of E17K Akt1 by blocking binding of the Pleckstrin Homology Domain of Akt1 
to the PIP3 substrate. 
 
4.2 Materials and Methods 
4.2.1 Screen for Biligand Peptide 
 The anchor determined above – yleaf – was scaled up with a biotin on the N-terminus for 
detection, a PEG5 linker between the biotin and the peptide, and a d-propargylglycine (Pra) on the 
C-terminus as the in situ click handle (Biotin-PEG5-yleaf-Pra).  Screens were performed using a 
library with 100% Met coupled at the C-terminus for potential MALDI TOF/TOF sequencing.  The 
library consisted of a comprehensive 5-mer containing 18 unnatural D-amino acids, excluding Met 
and Cys due to stability reasons.  The N-terminus of the library was appended with an azide click 
handle with a 4 carbon chain (Lys(N3))– for in vivo click with the Pra on the anchor peptide.  
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Screens were performed with 300mg of dried library beads swelled at least six hours in 1x TBS 
(25mM Tris-Cl, 150mM NaCl, 10mM MgCl2, pH = 7.5) buffer. 
 
Preclear (Figure 5a): 
 Swelled library beads 
were blocked overnight in 5% 
w/v dried non-fat milk in 1x 
TBS, then washed with 1x TBS 
three times.  The beads were 
incubated with a 7.15μM solution of the anchor peptide - Biot-PEG5-yleaf-Pra for one hour, then 
washed three times with 1xTBS.  Five milliliters of a 1:10,000 dilution of streptavidin-alkaline 
phosphatase conjugate in 0.5% milk in TBS was added to the beads, and incubated with shaking 
at room temperature for one hour.  The beads were washed with a high-salt TBS buffer (1x TBS 
plus 600mM NaCl) three times, then let shake in high salt buffer for one hour.  The beads were 
then washed three times with BCIP buffer (100mM Tris-Cl, 150mM NaCl, 1mM MgCl2, pH = 9.0) 
and developed by adding 15mL BCIP buffer plus 13μL BCIP and 26μL NBT to the beads in a 150mm 
polystyrene tray.  After one hour, the purple beads were removed by pipette and discarded.  The 
remaining beads were incubated in NMP for four hours to remove trace purple precipitate from 
the BCIP/NBT reaction, then were washed five times with methanol, five times with water, five 
times with TBS and blocked overnight in 5% milk. 
 
Target Screen (Figure 5b): 
 The clear beads remaining from the preclear were blocked in 5% milk in 1x TBS for two 
hours.  They were then washed three times with 1x TBS.  A pre-incubated solution of E17K mutant 
 
Figure 4-1: Biotin – PEG5 – yleaf – Pra: Biligand screens were performed 
using the yleaf anchor (red) with a PEG5 spacer (black) and a biotin tag 
(blue). MALDI-TOF MS, expected [M+Na] 1319.62, observed 1319.89. 
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protein (715nM) and anchor ligand (7.15μM) in 3mL of 0.5% milk was added to the blocked library 
beads and incubated for either five hours or overnight to allow an in situ click reaction to occur.  
In the morning, the beads were washed three times with 1x TBS, then incubated with a 1:4,000 
dilution of an anti-His Alkaline Phosphatase conjugated antibody (Abcam) in 0.5% milk for one 
hour.  The beads were then washed three times with a high salt TBS, then incubated on the 
shaking arm for one hour with the high salt buffer.  They were then washed three times with BCIP 
buffer, and developed as previously.  Hit beads turned purple and were removed and washed in 
NMP for four hours to decolorize, then guanidine-HCl to denature and remove and remaining 
protein.  The beads were then washed ten times with water and blocked in 5% milk overnight. 
 
Off-Target Anti-Screen (Figure 5c): 
 The beads from the target screen were washed three times with 1x TBS, then incubated 
with the off-target, wildtype PHD protein in 0.5% milk for one hour on the shaking arm at room 
temperature.  The beads were washed three times with 1x TBS, then incubated with a 1:4,000 
dilution of Anti-His Alkaline Phosphatase conjugated antibody in 0.5% milk for one hour at room 
temperature.  They were then washed three times with high salt buffer and let shake for one hour 
in high salt at room temperature before being washed three times with BCIP buffer and developed 
as previously.  The beads that turned purple bind to both mutant and wildtype protein or to the 
anti-his antibody, and were set aside.  The beads that remained clear were picked and washed 
with guanidine-HCl to remove any bound proteins, and blocked in 5% milk overnight. 
 
Product Screen (Figure 5d): 
 The beads specific for the mutant PH domain were washed three times with 1x TBS.  They 
were then incubated with a 1:10,000 dilution of Streptavidin – Alkaline Phosphatase conjugate in 
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0.5% milk for one hour.  The beads were washed three times with high salt TBS, then let shake for 
one hour with high salt buffer before being washed three times with BCIP buffer and developed 
as previously.  The beads that turned purple contained the anchor peptide covalently bound to 
the bead, and had formed a protein-catalyzed in situ click reaction.  These beads were collected 
and stripped with guanidine-HCl for one hour, washed ten times with water, and sequenced via 
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4.2.2 Streptavidin-Agarose Immunoprecipitation (Pull-down) Assays to Test 
Biligand Candidates (Figure 4-6) 
 Four biligand candidates were segregated based on their hydrophobicity and sequence 
homology using principal component analysis as for the anchor ligands screened in Chapter 3.  
Biligands were synthesized by coupling the 2° ligand onto Rink Amide Resin on the Titan peptide 
synthesizer.  The amide group on the end of the Lys(N3) was capped by shaking the resin with 2mL 
acetic anhydride, 2mL NMP and 0.5mL DIEA for three times for 10 minutes each time, then 
washed with NMP.   FMOC-Propargylglycine-Otbu (Pra) was clicked onto the Lys(N3) on the 2° 
ligand by incubating 2 equivalents of the Pra amino acid with 2 equivalents of CuI and 2 
equivalents of ascorbic acid with 1 equivalent of azide on the resin in 20% piperidine/NMP for 3 
 
Figure 4-2: Screening Strategy for Biligand Determination: (a) Preclear: Any library beads that bind to the screening 
reagents are removed. (b) Target Screen: Precleared beads are incubated with the target and anchor ligand and allowed 
to “click.”  The presence of the his-tagged PH Domain is detected via an anti-His antibody.  (c) Anti-Screen: Hit beads 
from the target screen are incubated with the off-target PH Domain and anti-his antibody.  These hit beads bind to both 
the target and off-target (WT and E17K mutant). (d) Product Screen: The beads are probed with streptavidin-alkaline 
phosphatase to determine which contain the click product and, thereby, have shown biligand formation. 
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hours.  The resin was washed five times with 4 mL of a chelating solution consisting of 1g sodium 
diethyldithiocarbamate in 20mL NMP and 1mL DIEA.  The anchor was then built onto the 2° ligand 
on bead, and an N-terminal PEG5-biotin tag were added.   
 Assays were performed exactly as for the anchor ligands, except for two key differences.  The 
biligand assays were performed using 6ug of GST-tagged PHD protein, instead of the untagged 
PHD that was used in the anchor pull downs.  The pull-downs were also conducted out of 1% 
serum in 1x TBS, as opposed to just 1x TBS.  This is a much more demanding assay that tests not 
only the affinity, but also the selectivity of the ligands because they need to be able to bind to 
their target protein in a very complex medium.  The performance of the biligand candidates in 
this challenging assay indicates that they have little off-target interactions with a multitude of 
other proteins, and would perform well in the condition in which they will need to be detecting 





Figure 4-3: Lys(N3) - yleaf - Tz - yksy - PEG5 – Biotin: MALDI-TOF MS 
expected 2248.1, observed [M+H] 2249.1. 
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4.2.3 Screen for Triligand Peptide 
 The best biligand candidate as determined in immunoprecipitation assays – yleaf–(triazole, 
Tz)-yksy - was scaled up (Figure 4-3) with a C-terminal PEG5-biotin for detection during the assay 
by coupling PEG5 onto NovaTag Biotin resin (EMD).  Lys(N3)-yksy was coupled onto the resin on 
the Titan peptide synthesizer, and FMOC-Pra-Otbu was clicked on as previously.  The remaining 
“Lys(N3)-yleaf” portion was then synthesized on the Titan, the Lys(N3) serving as the click handle 
for the triligand screen.  The screens (Figure 4-4) were completed using a random 5 D-amino acid 
library with a C-terminal D-propargylglycine alkyne click handle, and were otherwise performed 
exactly as for the biligand, including all concentrations.  Three hit beads were discovered in this 
screen, and the first hit had a nonsensical sequence, so it could not be used.  Both of the usable 
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4.2.4 Full ELISA Curves for Ligands 
 The full curve ELISAs were obtained using streptavidin coated ELISA plates (Pierce).  The 
ligands – anchor, biligand, two triligand candidates (ivdae and iryrn) and “eflya” scrambled anchor 
peptide blank - were laid down on the plate at a concentration of 1μM for one hour.  Two lanes 
of each ligand were used on the plate for both proteins – WT and E17K GST-PHD. The plates were 
blocked with 5% BSA for two hours.  Dilutions of both WT and E17K GST-PHD proteins were made 
in 0.5% BSA in 1xTBS ranging from 1μM down to 0.5nM by serially diluting 1:2 down a series of 8 
samples.  For each ligand, a no protein blank was also used.  The proteins were incubated with 
 
Figure 4-4: Screening Strategy for Triligand Determination: (a) Preclear: Any library beads that bind to the screening 
reagents are removed. (b) Target Screen: Precleared beads are incubated with the target and biligand and allowed to 
“click.”  The presence of the his-tagged PH Domain is detected via an anti-His antibody.  (c) Anti-Screen: Hit beads from 
the target screen are incubated with the off-target PH Domain and anti-his antibody.  These hit beads bind to both the 
target and off-target (WT and E17K mutant). (d) Product Screen: The remaining beads are probed with streptavidin to 
determine which contain the click product and, thereby, have shown triligand formation. 
  92 
the blocked plate for one hour, washed three times with 1xTBST + 0.5% BSA and tapped dry, then 
detected with a 1:10,000 dilution of an HRP conjugated anti-GST ab.  The plate was again washed 
three times with 1xTBST and tapped dry.  It was developed with a 1:1 solution of TMB substrate, 
and development was stopped with 1M H2SO4 and read on a plate reader.  The curves were 
plotted by normalizing the signal by the blank wells, and were fitted by a Hill function in GraphPad 
using a common saturation and slope (Bmax = 1.466 +/- 0.03, h = 0.7383 +/- 0.025). 
 
4.2.5 Point ELISA Assays for Triligand Binding to Akt1 and Akt2 Wildtype and 
E17K Mutant Proteins 
These assays were conducted to test the binding of the triligand to the off-target Akt2 
wildtype and mutant proteins.  For this assay, all samples were taken in triplicate for statistical 
purposes.  Triligand peptide was first immobilized onto Neutravidin ELISA plates (Pierce) for one 
hour.  A scrambled anchor peptide, eflya, was used as the no-ligand blank, as the GST proteins 
have significant background binding to a blank Neutravidin plate.  The plates were then blocked 
with 5% BSA overnight.  Protein was laid down on the plate at a concentration of 100nM for 
samples wells and the blank, scrambled peptide wells.  GST protein alone (Abcam) was also 
incubated with the triligand and scrambled peptide as a control.  The proteins were incubated for 
one hour, then washed three times with 1xTBST.  The protein was then detected with 1:10,000 
anti-GST mouse mAb (Fisher, #MA4-004) for one hour, washed three times with 1xTBST, and 
developed with a 1:1 mixture of TMB substrate for ten minutes.  The samples were plotted by 
subtracting the blanks and averaging the sample wells.  The highest signal was considered 100% 
binding, and the other samples were normalized accordingly. 
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4.2.6 PIP3 Agarose Inhibition Assays 
PIP3 Agarose beads (Echelon) were used to detect for the inhibition of PH Domain binding 
to its substrate, PIP3, upon incubation with the anchor candidate peptide ligands.  To test the 
inhibition of each of the ligands, anchor biligand and triligand, 20μL of resin slurry was added to 
each of four tubes, and washed three times with 1x TBS.  Protein, 2μg (234nM) of E17K mutant, 
was pre-incubated for one hour at room temperature with either DMSO (no peptide ligand blank), 
anchor, biligand or triligand at 2.38μM (10x in relation to protein) in 200μL of 1x TBS.  For the 
control, mutant PH Domain was incubated with 1x TBS and 1μL DMSO to mimic the ligand 
conditions.  These protein samples were then added to PIP3 agarose in a Spin-X tube and 
incubated at room temperature for two hours.  The resin was washed three times with 1x TBS 
with 0.25% IGEPAL CA-630, spun out to dry completely, then denatured with 50μL 3x SDS gel 
loading buffer for 10 min at 95°C.  The gel loading buffer was spun out of the resin and detected 
via western blot as per the streptavidin – agarose pull downs.  Inhibition was indicated by a 
decrease in the amount of PH Domain that was pulled down by the resin. 
 Expanded inhibition blots with either wildtype of E17K mutant protein were performed in a 
similar fashion.  Twelve tubes of 20μL of PIP3 agarose were washed three times with 1x TBS.  2μg 
of either wildtype or mutant PHD-GFP protein (234nM) in 200uL 1xTBS were pre-incubated for 30 
minutes with differing concentrations of triligand: 0.1eq (23.4nM), 1eq (234nM), 10eq (2.34μM), 
100eq (23.4μM), and 1000eq (234μM).  The protein and triligand solutions were then incubated 
with the PIP3 resin for 2 hours at room temperature.  The resins were washed, eluted, and blotted 
as per all PH Domain western blots.   
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4.3 Results and Discussion 
4.3.1 Biligand Development 
It was hypothesized that a similarly targeted, but bulkier PCC Agent might serve as a steric 
blocker of the PHD-PIP3 interaction.  To this end, two cycles of iterative in situ click chemistry 
screens were designed to develop the yleaf ligand into a biligand and then a triligand.  To identify 
the biligand (the first iterative cycle, Figure 4-2), the yleaf ligand was modified to present an 
alkyne at the C-terminus, and a PEG5-biotin group at the N-terminus (Figure 4-1).  This modified 
ligand (called an anchor ligand) was then co-incubated with an alkyne-presenting OBOC library 
and the (unmodified) E17K PHD.  Successful hits are those in which the E17K PHD promotes the 
click coupling of the anchor ligand onto a library peptide, and those hits are detected by screening 
for the formation of this clicked product (Figure 4-2).  Those hits are candidate 2o ligands (Table 
4-1).  As with the discovery of the anchor ligands, the biligand hits are clustered according to their 
hydrophobicity and sequence homology using principle component analysis.  These hits cluster 
into groups, as seen in Figure 4-5, and unique clusters are circled.  Hits from these different 
clusters, thus representing the sequence diversity of the screen, were chosen to be scaled up and 
tested for both affinity and selectivity to the E17K mutant PH Domain protein.  For testing, the 2o 
ligand candidates are appended to the yleaf anchor ligand via a Cu(I) catalyzed 1,4 triazole, to 
mimic the triazole formed by the protein target during the screen to form a biligand.  The biligand 
candidates are then subjected to immunoprecipitation assays (pull down) to identify a candidate 
biligand in a manner that is similar to what was done to identify the original yleaf ligand (Figure 
4-6).  The biligand in lane 6 in Figure 4-6, yleaf – yksy, shows the highest affinity for the E17K 
mutant protein while still maintaining the selectivity over the wildtype protein.  This sequence 
was chosen as the biligand. 
 
 














Figure 4-5: Clustering of Biligand Sequence Ligands by AA Similarity: Hit sequences from the biligand screen were 
analyzed by their hydrophobicity and sequence homology using principal component analysis.  Clusters circled in green 
indicate clustered regions, and the cyan circles indicate the peptide that was selected and scaled-up as a possible 
biligand sequence.  The potential biligand sequences that were tested are: yleaf-ywrl, yleaf-yksy, yleaf-rdyr, and yleaf-
hyrw, where “yleaf” is the anchor ligand and the “-“ indicates the location of the triazole linkage. 
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Table 4-1: Hit Sequences from Biligand Screen 
Az4 h w p r 
Az4 n v y l 
Az4 h y r w 
Az4 r d y r 
Az4 y n y k 
Az4 y k t w 
Az4 s r f y 
Az4 y k s y 
Az4 y y s r 
Az4 r h w s 
Az4 p w w r 
Az4 n f r y 
Az4 y w r l 
Az4 y w k G 
Az4 a y l y 
Az4 h w r w 
Az4 n w r l 
Az4 a a r w 
Az4 G r w y 
Az4 w f r i 
Az4 r p y y 
Az4 v w f r 
 
 
Figure 4-6: Pull-down Assay Results for Biligand Candidates: Note that all of the biligand candidates improve 
upon the binding of the anchor ligand, but yleaf-yksy shows the greatest signal in binding the E17K protein and 
the lowest in binding the WT protein.  This biligand was chosen as the candidate biligand and carried on to 
triligand screening. 
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4.3.2 Triligand Development 
Once a candidate biligand has been identified, it is then similarly modified to form a new 
anchor ligand (Figure 4-3), which is then similarly screened (Figure 4-4) to identify a triligand.  
There were only 3 hit sequences from this triligand screen, and one sequence was not able to be 
called due to low signal and an irregular sequence, seen in Table 4-2. Because there were only 
two valid hits from this screen, both were scaled up and tested in a full-curve ELISA assay (Figure 
4-7).  The iryrn triligand showed significantly improved affinity for the E17K PH Domain, but this 
benefit was offset by the drastic increase in affinity for the wildtype PH Domain.  The ivdae 
triligand maintains the selectivity seen in the anchor ligand and was chosen as the triligand, whose 
structure is shown in Figure 4-8. 
 
Table 4-2: Hit Sequences from Triligand Screen 
G l - - m - 
i r y r n Pra 





Figure 4-7: ELISA assays for affinity and selectivity of triligand candidates.  The iryrn triligand seen in red 
shows a significant affinity increase, but loses much of the selectivity for the E17K mutant PH Domain 
(triangles).  The ivdae maintains the selectivity and affinity of the anchor ligand, and was carried forward 
as the triligand. 
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Binding curves that compare the yleaf ligand with the biligand and triligand PCC agents 
are shown in Figure 4-9.  Likely because the expanded binding site for these larger PCC agents 
grows away from the location of the E17K point mutation, increasing the affinity while 
maintaining the selectivity of the final PCC agent upon the addition of these secondary and 
tertiary arms proved challenging.  For example, the biligand exhibited an increase in affinity for 
the E17K mutant protein, but this is offset by an even larger increase in affinity for the WT protein.  
However, at the triligand stage, the selectivity for E17K Akt1 relative to WT Akt1 is largely 
recovered.   
Additionally, there is a slight preference for E17K Akt1 relative to E17K Akt2 (Figure 4-10).  
The homology of the PHD between these isoforms is 79%, as calculated by a pairwise sequence 
analysis using Blast2Seq between the Akt1 E17K structure (PDB ID: 2UZR) and the Akt2 PH Domain 
structure (PDB ID: 1P6S).  The binding curves of 4B yield EC50 values for the E17K Akt1 of 61nM, 
19nM, and 45nM for the yleaf ligand, the biligand and the triligand, respectively.  
 
Figure 4-8: Structure of final triligand: ivdae – Pra – Lys (N3) – yleaf – Pra – Lys (N3) - yksy 







Figure 4-9: Full ELISA curves of Anchor, Biligand, and Triligand.  The ELISAs show that 
the biligand (red) has an increased affinity for the E17K PH Domain from the anchor ligand 
(blue), but also for the wildtype protein.  The triligand (green) restores the affinity and 
selectivity of the anchor ligand. 
 
Figure 4-10: Point ELISA of Triligand binding to Akt1 and Akt2. 
The binding to both the wildtype and E17K mutant PH Domains 
was tested for both Akt1 and Akt2.  The triligand maintains the 
selectivity for the E17K in both proteins, and shows only a slight 
preference for the Akt1 isoform. 
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4.3.3 Inhibition Assays 
The yleaf ligand, the biligand, and the triligand were all tested for their ability to block the 
E17K PHD binding with PIP3 (Figure 4-11).  For this test, 
PIP3-coated resin (Echelon Biosciences) was used to 
mimic the PHD interaction with the cell membrane, and 
could be used to bind the protein as in an 
immunoprecipitation assay3.  The presence of an 
effective blocking compound would reduce the ability 
of the resin to capture the protein, and would thus 
appear as a diminished signal in the corresponding western blot assay.  A control lane containing 
no capture agent was used to show baseline binding of the protein to the PIP3 resin.  As 
mentioned above, the yleaf ligand produced no change in E17K binding ability, but both the 
biligand and triligand exhibited the ability to block the PHD-PIP3 interaction, with the triligand 
being the most effective (Fig 4D).  In an expanded study, we compared the amount of E17K and 
WT PHD binding relative to the amount of added triligand.  This assay shows significant selective 
inhibition (by around 103) of the E17K mutant relative to the WT. 
 
Figure 4-11: PH Domain membrane binding 
in the presence of each ligand. The first lane, 
blank, shows the amount of protein binding to 
PIP3 with no ligand.  Anchor ligand in respect 
to protein shows no decrease in binding, but 
binding is starting to be blocked with the 
biligand and triligands. 
 
Figure 4-12: Expanded Inhibition Assay. The wildtype or E17K mutant PH Domains were 
incubated with varying amounts of triligand.  The wildtype protein shows very little 
reduction in binding until 1000x triligand to protein.  The E17K PH Domain, however, shows 
a significant drop in binding almost immediately. 
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4.4 Conclusions 
The epitope-targeting strategy allowed for such selective targeting of the E17K mutant PH 
Domain that selectively blocking the oncogenic activation of this protein was the logical next step.  
Bulking up the original anchor into a triligand covered more of the PH Domain PIP3 binding pocket, 
therefore blocking PIP3 binding.  By ensuring that the triligand maintained its selectivity for the 
E17K mutant PH Domain, the ligand demonstrates significantly reduced interference with the 
wildtype PH Domain protein.  The blocking of the E17K protein binding to the cell membrane 
demonstrates the ability of this click-focused epitope screening technology to produce not only 
selective binding agents, but also potential therapeutics that could show significantly decreased 
toxic side-effects due to the reduction in off-target and healthy-cell interactions.   
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 Chapter 5 
 
Extending OBOC in situ Click Chemistry into a 
Phage Display System 
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5.1 Introduction 
5.1.1 Azide-Containing Phage Display Libraries 
  Recent advances in chemical biology have made it possible 
to incorporate unnatural amino acids into recombinant proteins1.  
Schultz et al. has shown that through the use of amber suppression, 
azide-containing amino acids can be incorporated at specific 
locations into the pIII coat protein on an M13 phage2.  The goal of 
this project is to synthesize a randomized 7-amino acid phage display 
peptide library containing an azide amino acid at a fixed position coded by an amber stop codon 
(TAG) to translate the click product screening technology into a biological library screening, and 
to demonstrate the use of resulting azide-phage library in in situ click screening.  
The 7-randomized amino acid library will dramatically increase the number of peptide 
sequences that can be panned in each screen.  For comparison, a complete OBOC library of 5 
amino acids is sampled in 660 mg of library beads. To sample each sequence one time in a library 
the size of the 7-mer, it would require 447g of beads –-a practically impossible task using our 
current methods!  In the phage display screen, however, it is trivial to completely oversample this 
7-mer library 100 times in each screen–a huge advantage of the biological display technique.  The 
strategies for discovering PCC agents with these libraries should be nearly identical to those 
previously developed for the OBOC click libraries, except that a much greater sequence space can 
be sampled with each screen due to the physical size of the library, and screening and sequencing 
steps can be performed significantly faster. 
 
 
Figure 5-1: Azido - phenyl 
alanine amino acid to be 
incorporated in phage 
library. 
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5.1.2  Mirror-Image Phage Display 
 One of the disadvantages common to 
phage display is that the library will contain 
exclusively L-amino acids, and will therefore 
produce a peptide sequence that is susceptible 
to protease cleavage.  In order to avoid this 
potential problem, a technique called “mirror-
image phage display” (Figure 5-2) has been developed.  In this technique, an L-amino acid phage 
library is screened against a target synthesized from D-amino acids in order to find a D-peptide 
that binds to the L-target4, where the D-target forms an exact mirror image of the L-target.  
Therefore, screening against a mirror image of the target and reversing the stereochemistry of 
the hit peptide binder produces a D-ligand that binds to the original L-target.  With the epitope-
targeting strategy currently used for PCC agent discovery in the lab, where a chemically-
synthesized portion of the protein is used as a target for screening, it is trivial to prepare a D-
amino acid epitope for use in a mirror image phage display screen.  Using this technique, an azide-
containing phage library can be screened in order to develop D-amino acid PCC agents, effectively 
converting the click screening so crucial to our success in PCC ligand discovery from an expensive 
and time-consuming OBOC library method to a simpler, quicker biological screening process.   
 
5.1.3 G6PD Capture for Malaria Eradication 
 The Bill and Melinda Gates foundation is calling for the eradication of malaria, but this is 
a serious challenge that can only be addressed through the elimination of asymptomatic and 
chronic infections5.  There exists currently a family of drugs, the 8–aminoquinolines such as 
primaquine, which can completely clear a person of infection (termed a “radical cure” regimen) 
and can thereby reduce the transmission of the disease6.  Unfortunately, people with a glucose–
 
Figure 5-2: Mirror-Image Phage Display Technique3. 
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6–phosphate dehydrogenase (G6PD) deficiency, the most common enzymatic deficiency in the 
world, risk severe and life-threatening reactions to the standard treatment with this medication, 
which in turn requires a significantly different dosing method to effectively cure patients with a 
G6PD deficiency7.  Therefore, in order to successfully employ the primaquine “radical cure” 
strategy for malaria eradication, effective methods to rapidly determine a patient’s G6PD activity 
need to be developed immediately so that it is possible to administer the appropriate dose of the 
medication as quickly as possible6. 
 The G6PD is found in red blood cells, and assists in the formation of NADPH from NADP+, 
conferring protection from oxidative stress.  Deficiencies normally arise from mutations in the 
G6PD gene that produce proteins with less than optimal function, reducing the overall enzymatic 
activity6.  There are about 140 known mutations of this protein, most of which are single base 
changes, which can adversely affect the  G6PD activity7.  Current gold standard assays measure a 
deficiency by performing enzymatic tests on blood samples, measuring the amount of converted 
NADPH per unit of blood.  Unfortunately, patients who have recently undergone a hemolytic 
event, causing a mass death of old red blood cells, show a false normal test.  This is due to the 
higher than normal prevalence of young red blood cells, which express a higher G6PD copy 
number than mature red blood cells, compensating for the reduced activity of the enzyme caused 
by the mutation6.   
 The goal of this project is to develop a capture agent that universally detects G6PD in all 
of the possible mutant forms in order to capture the protein to a chip where the concentration 
and the activity of the G6PD in the blood can be measured simultaneously.  Such a diagnostic test 
can normalize the G6PD activity to protein copy number as opposed to activity per unit of blood, 
resulting in much fewer false positives and faster treatment of malaria.  This combination test 
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should help reduce the number of false normal blood test results, allowing for significant progress 
toward the eradication of malaria. 
 
5.2 Materials and Methods 
5.2.1 Preparation of Plasmid for Incorporation of Azidophenylalanine and Amp 
Resistant Gene 
The plasmid pAC-DHPheRS-6TRN (Figure 5-3) containing the coding sequences for 
Methanococcus jannaschii amber suppressor tRNATyr (MjtRNA) and the mutant M.jannaschii 
tyrosyl-tRNA synthetase (MjTyrRS) was a gift from Dr. Zhiwen Zhang at Santa Clara University.  
This plasmid was originally designed for the site-specific incorporation of 3,4-dihydroxy-L-
phenylalanine (DOPA); its mutant MjtRNA recognizes TAG as a codon, and the mutant MjTryRS 
recognizes DOPA as a substrate. It also harbors a tetracycline-resistance selection marker. Since 
the host E. coli strains used for the phage production and in subsequent studies carry a TetR 
marker in their F’ episomes, the TetR gene in this plasmid was first replaced with a beta-lactamase 
(AmpR) gene for ampicillin selection, to be compatible with the antibiotic resistance of the host.  
Nine point mutations based on the description by Tian et al.2 were then introduced into the 
MjTyrRS synthetase so that the resultant synthetase recognizes the azidophenylalanine amino 
acid instead of the DOPA. 
To perform the TetR -> AmpR switch, the AmpR gene was amplified from a pET-3a plasmid 
by polymerase chain reaction (PCR) using the primers shown in Table 5-1.  The PCR product and 
the original TetR-containing suppression plasmid were digested with HindIII and EagI, and ligated 
to produce slow-growing colonies on an LB-agar plate supplemented with 100 µg/mL ampicillin.  
Final clones were confirmed by DNA sequencing (Laragen).  
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Table 5-1: Primers for AmpR Switch.  
Primer Sequence 
Hind_bla_5 GCG AAG CTT TAA TGC GGT AGT TTA TCA CAG TTA AAT TGC TAA CGC 
AGT CAG GCA CCG TGT ATG AGT ATT CAA CAT TTC CGT GTC GCC C 
Eag_bla_3 ATA CGG CCG TTA CCA ATG CTT AAT CAG TGA GGC ACC TAT CTC AGC G 
 
 Based on the previous work by Tian et al.2, nine point mutations were introduced into the 
mutant MjTyrRS gene to change its substrate specificity from DOPA to azidophenylalanine: E25K, 
L32T, S67A, N70H, E107N, D158P, I159L, L162Q, and Q167A. All mutagenesis reactions were 
carried out using QuikChange Kit (Stratagene) according to the manufacturer’s instructions.  Table 
5-2 lists the primers used in the order of performed reaction.  Each QuikChange reaction was 
independently verified for the correct sequence, and the final plasmid was completely sequenced 
to ensure correctness.  The resulting final plasmid was named pAC-AzPherS-6TRN.  
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Figure 5-3: pAC-DHPheRS-6TRN Plasmid.  Plasmid for the incorporation of Azidophenylalanine.  Red boxes are the six 
copies of the M. jannaschii tRNATyrCUA.  Green indicates the synthetase.  Blue is the Amp resistant gene, and the pink 
is the Chloramphenicol resistant marker containing an amber codon used to indicate successful incorporation. 
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Table 5-2: Primers used for the DOPA -> Azidophenylalanine Synthetase QuikChange Reactions.  The 
number in the primer name indicates the order in which the QuikChanges were performed, and the mutation is 
included in the name of the primer. 
Primer Name/Mutation Sequence 
1_G73A_Upper AGG AAG AGT TAA GAG AGG TTT TAA AAA AAG ATG AAA 
AGT CTG CTC T 
1_G73A_Lower AGA GCA GAC TTT TCA TCT TTT TTT AAA ACC TCT CTT AAC 
TCT TCC T 
2_G319A_A321C_U TTA AAG GCA AAA TAT GTT TAT GGA AGT AAC TTC CAG 
CTT GAT AAG GAT TAT ACA CTG 
2_G319A_A321C_L CAG TGT ATA ATC CTT ATC AAG CTG GAA GTT ACT TCC 
ATA AAC ATA TTT TGC CTT TAA 
3_T199G_A208C_U TGC TGG ATT TGA TAT AAT TAT ATT GTT GGC TGA TTT 
ACA TGC CTA TTT AAA CCA GAA AGG AG 
3_T199G_A208C_L CTC CTT TCT GGT TTA AAT AGG CAT GTA AAT CAG CCA 
ACA ATA TAA TTA TAT CAA ATC CAG CA 
4_C94A_T95C_T96C_U GAG GTT TTA GAA AAA GAT GAA AAG TCT GCT ACC ATA 
GGT TTT GAA CCA AGT GGT AAA ATA CAT 
4_C94A_T95C_T96C_L ATG TAT TTT ACC ACT TGG TTC AAA ACC TAT GGT AGC 
AGA CTT TTC ATC TTT TTC TAA AAC CTC 
5_G472C_A473C_T474G_A475C_U GGT TGC TGA AGT TAT CTA TCC AAT AAT GCA GGT TAA 
TCC GCT TCA TTA TTT AGG CGT CGA TGT 
5_G472C_A473C_T474G_A475C_L ACA TCG ACG CCT AAA TAA TGA AGC GGA TTA ACC TGC 
ATT ATT GGA TAG ATA ACT TCA GCA ACC 
6_T484C_T485A_U TAT CCA ATA ATG CAG GTT AAT GAT ATT CAT TAT CAA 
GGC GTC GAT GTT CAG G 
6_T484C_T485A_L CCT GAA CAT CGA CGC CTT GAT AAT GAA TAT CAT TAA 
CCT GCA TTA TTG GAT A 
7_C499G_A500C_U CAT TAT TTA GGC GTC GAT GTT GCG GTT GGA GGG ATG 
GAG C 
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5.2.2 Test of Azidophenylalanine Incorporation into a Protein in E.coli 
The ampicillin-resistant vector pAC-AzPheRS-6TRN developed above also carries a 
chloramphenicol acetyltransferase (CAT or CmR) gene where residue D112 is mutated to an amber 
stop codon.  E. coli TOP10-F’ cells were transformed with pAC-AzPheRS-6TRN plasmid and plated 
on an LB agar plate supplemented with ampicillin (100 µg/mL and tetracycline (12.5 µg/mL). 
Colonies were slow-growing, and were therefore incubated for 24 hours at 37C°.  An LB broth 
culture of 5 mL supplemented with ampicillin (100 µg/mL) and tetracycline (12.5 µg/mL) was 
inoculated with a single colony and grown overnight at 37°C. The overnight culture (1 mL each) 
was diluted into two 7 mL cultures with appropriate antibiotics. An azidophenylalanine stock 
solution was prepared freshly by dissolving the amino acid in 50% DMSO and 50% acidic water 
(pH = 2.0 with HCl). A blank stock solution containing only the DMSO/acid without amino acid was 
also prepared.  The amino acid (or blank) stock solution was added to the diluted culture to the 
final concentration of 2 mM (or 0 mM) azidophenylalanine. After incubating at 37°C for two hours, 
34 µg/mL of chloramphenicol was added to each culture.  Each culture was allowed to grow 
further at 37°C, and the level of growth was assessed by OD600 at 6 and 18 hours of incubation. 
 
5.2.3 Test of Azidophenylalanine Incorporation into M13KE Phage 
Four phage clones with variable display sequences of [Amber]-AHEATH, [Amber]-SHEATH, 
[Amber]-RHEATH, [Amber]–THEATH in M13KE phagemid were purchased from Antibody Design 
Labs. M13KE phagemid also contains the lacZα gene for blue/white plaque screening.  A naturally-
amber-suppressing strain of E. coli XL1 Blue was transformed with each individual clone, and 
plated on LA agar plate supplemented with tetracycline (12.5 µg/mL), IPTG (50 µg/mL) and X-gal 
(40 µg/mL) in top agar following the procedure described in Ph.D. Phage Display Libraries Manual 
(New England Biolabs, ref).  An overnight starter culture of E. coli Top10-F’ transformed with pAC-
AzPheRS-6TRN was diluted 10-fold into 10 mL of LB supplemented with ampicillin (100 µg/mL) 
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and tetracycline (12.5 µg/mL ) and grown at 37°C in the presence of 2mM azidophenylalanine for 
two hours.  A blue plaque from each individual clone was added to the culture from the fresh 
plates, and cultures were further incubated for five hours.  The cultures were centrifuged at 4500 
rpm to remove the cells, and the phages were precipitated overnight at 4°C by collecting the top 
8 mL of the supernatant and mixing it with 1.6 mL of 20% (w/v) PEG-8000 in 2.5M NaCl (PEG/NaCl).  
An alkyne-labeled TAMRA dye was clicked onto the azide moiety on the azidophenylalanine-
containing phages using the Click-It Kit (Invitrogen) according to the manufacturer’s instructions, 
and the resulting phages were resolved by SDS-PAGE.  The gel was then imaged on a Typhoon 
imager using the preset settings for TAMRA dyes. 
 
5.2.4 Synthesis of M13KE Azidophenylalanine-Terminated 7-mer Random Library 
The peptide library was designed to have the following sequence when expressed on the 
surface of the pIII coat protein of the M13KE phage: A-[Amber]–X1X2X3X4X5X6X7–G-L-V-P-R-G-S-pIII 
protein.  The N-terminus of the display sequence has a fixed alanine amino acid to provide a non-
charged spacer at the signaling peptide cleavage site to ensure proper expression of the azide-
incorporated final pIII protein.  The amber codon, the site of the azidophenylalanine 
incorporation, follows the N-terminal alanine, and precedes then the randomized 7-mer amino 
acid region.  This library sequence is separated from the rest of the pIII protein by a thrombin 
cleavage site (LVPRGS) to allow the enzymatic cleavage of a “clicked” phage hit from a matrix- 
immobilized target. 
The phage library was built by Antibody Design Labs using standard NNK codon, where N 
encodes an equimolar amount of cytosine, guanine, thymine or adenine bases, and K encodes 
only guanine or thymine.  By designing the library in this fashion, some of the redundancy of the 
third codon as well as two of the three possible stop codons, TAA and TGA, are eliminated.  
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The final DNA library contained about 7.65 x 108 total transformants, and about 90% of 
that library contained inserts for a total sequence diversity of 6.9 x 108.  It should be noted that 
there is a significant prevalence for guanine at the first position of a codon, as can be seen in 
Figure 5-4.  This leads to a greater prevalence of the Glycine (G) amino acid in the overall 
distribution (Figure 5-5).  Stop codons and Cysteine (C) amino acids are repressed since the 
production of functional phages is prohibited with these sequences, which is to our benefit.  The 











Figure 5-4: Distribution of Random Nucleotides.  There is a significant prevalence for G in 
the first position, for unknown reasons.  Recall that the third position is limited to T and G 
due to the NNK format of the library. 













5.2.5 Design and Synthesis of G6PD Target and Scrambled Target for Screening 
The capture agent that will effectively detect G6PD in clinical settings must be able to bind 
to a site on the protein surface that has 
the least rate of mutation in order to 
ensure the most efficient capture of the 
protein with diverse sequence variance.  
As seen in Figure 5-6, exons 2 and 3 have 
the least number of total mutations 
identified in the polypeptide sequence.  
There are also no Class I mutations that correlate to the most severe deficiencies in enzymatic 
activity.  Therefore, these two exons are the ideal location to target in order to capture the most 
diverse pool of mutant G6PD proteins.  The region that is targeted by the capture agent should 
 
Figure 5-5: Distribution of Amino Acids.  The high prevalence of the G base pair in the first position lead to a 
much higher prevalence of the G amino acid than was expected.  Otherwise, the distribution is as to be 
expected. 
 
Figure 5-6: Location of G6PD Mutations in protein.  Exons 2 and 
3 show the least number of mutations and no Class I mutations, 
so provide an ideal location to target. 
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also be distant from the NADP+ binding site in order not to interfere with the enzyme activity after 
capture.  In the crystal structure (PDB ID: 1QKI) in Figure 5-8, the region encoded by exons 2 and 
3 is unstructured in red in the bottom right of the protein.  This region is far from the active site 
seen in complex with the NADP+ at the top left of the protein, and the enzyme is expected to 
retain its original level of activity after being captured at this position. 
The region including these exons, seen in Figure 5-7, has a few sites commonly mutated, 
which are shown in red.  Therefore, the capture agent must be targeted to the amino acids shown 
in black in order to ensure it is not binding to a highly mutated section of the protein.  The epitope 
that was selected for screening consists of amino acids 20 – 31 corresponding to the sequence 
LFQGDAFGQSDT, and was synthesized on TentaGel resin using D – amino acids in order to use the 
mirror image phage display technique to produce a D - amino acid peptide to bind to the L - G6PD 
protein.  The synthetic target epitope was appended with propargylglycine (Pra) residue at the N-
terminus, providing an alkyne click handle.  A scrambled epitope also made of D – amino acids, 
[Pra]-GDAHSFQDTLQF, was synthesized on TentaGel as well, to be used in a preclear/antiscreen 
step for the library.  The target and scrambled target on TentaGel resin will allow the phage library 
to click onto the permanently-immobilized target so that very harsh washing conditions can be 
used to remove all but the covalently bound phages.  These peptide sequences were tested for 








Figure 5-7: Amino Acid Sequence of Exons 1 and 2 of G6PD.  The amino acids highlighted in red 
indicate frequently mutated positions, and the residues in black are generally conserved. 
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5.2.6 Optimized Phage Library Target Screening Conditions 
General protocols for phage library screening procedures including phage titering, scaling 
up, and sequencing as well as preparation of materials such as buffers, PEG/NaCl solution and top 
agar adopted from the NEB Ph.D. Phage Display Library System manual for M13KE, unless 
otherwise noted.  
The library from Antibody Design Labs was produced in a naturally-suppressing strain of 
E. coli TG1 that inserts Glu, or E, at the site of amber codon.  This library cannot be used for click 
screening, as there is no azide amino acid, but can be used for “target” screening to find peptide 
 
Figure 5-8: Crystal Structure of G6PD (1QKI).  This mutant G6PD in complex with NADP+ indicates that the 
unstructured regions encoded by exons 2 and 3 (bottom right in red, not entirely present in structure) are far from the 
active site of the protein.  Capturing the protein at this location should not affect enzyme activity. 
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sequences that bind to the G6PD epitope.  The target screening must be completed first, also 
because approximately 35% of this phage pool contains no insert, or “naked phages.” Naked 
phages have a significant selection advantage over those that would require the amber 
suppression.  The target screen is designed, therefore, to enrich for phage containing the library 
insert, and remove the naked phage from the phage pool before incorporation of 
azidophenylalanine is performed. 
The TentaGel beads containing the target and scrambled epitopes are stored in the form 
of 50% (v/v) slurry in 1:1 ethanol:water solution.  One hundred μL each slurry of the target and 
scrambled epitopes were washed with 1 mL Tris-buffered saline (TBS, 25mM Tris-HCl, 150mM 
NaCl, 10mM MgCl2) with 0.1 % Tween-20 (TBST), then blocked with 1mL of 5% (w/v) bovine serum 
albumin (BSA) in TBS for one hour at room temperature.  An antiscreen was performed by 
incubating the scrambled peptide resin with a phage screening solution containing 2 μL sterile 
filtered human serum, 2 μL of the original library (~5 x 1011 total phages), and 196 μL TBS for 30 
minutes at room temperature.  The beads are spun down and the supernatant, containing the 
phage that did not bind to the scrambled peptide, is added to the target epitope resin and 
incubated for one hour at room temperature.  Extensive washes are performed to ensure that the 
least number of non-specific and naked phages remain: five times with TBST, 30 minutes shaking 
in TBST, five times with TBST, five times with high salt TBS (2.5 M NaCl), 30 minutes shaking in 
high salt TBS, five times with high salt TBS, five times with TBST, five times with TBS, 10 minute 
shaking with TBS, five times with TBS, and two times with CaCl2 thrombin buffer (1 mM CaCl2 in 
TBS).  The last wash step is retained and titered to ensure no phage are eluting.  The target beads 
are then incubated with 4 units of thrombin in 200 μL CaCl2 buffer for 24 hours at room 
temperature to elute hit phages.  This step should elute only the phages that have a thrombin 
cleavage tag.  After incubation, the 200 μL of thrombin cleavage cocktail was removed from the 
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beads, and the beads were washed five times with 200 μL TBS to remove all of the cleaved phages. 
The washes were combined with the thrombin eluent.  The target beads are then acid-bumped 
by adding 1mL of 0.2 M glycine-HCl + 1mg/mL BSA buffer (pH = 2.0) for 10 minutes in order to 
ensure that all thrombin cleaved peptides were removed previously, and that only naked phage 
remain.  The 1mL of acid eluent was removed from the beads and neutralized with 150 μL of 1 M 
Tris (pH = 9.1).  Both the thrombin cleavage and acid bump eluents are titered to determine the 
number of phages eluted in each step.   
 
5.2.7 Testing Phage Plaques for Library Inserts 
The titered phage from a library or final eluent of a screen can be rapidly assessed for the 
presence of library inserts by plaque PCR before sequencing each individual clone from titered 
plaques.  The first two primers listed in Table 5-3 were designed by Antibody Design Labs, to 
recognize the DNA sequence on the M13KE phagmid on the either side of the cloning site, allowing 
the screening for the presence of insert based on the increased size of the PCR product compared 
to the one from a naked phage.  The last PCR primer is an alternate 3’ primer designed to recognize 
part of the insert DNA sequence, and therefore, a positive PCR reaction only occurs when the 
template phage contains the insert, and not with a naked phage.  At each stage of the screening 
process, plaques were picked, and plaque PCR was performed to determine the percent of naked 
phage. 
Table 5-3: Primers for Colony PCR of Inserts.  The first two primers show a slightly heavier PCR band if the insert 
is present.  The last primer is an alternate 3’ primer designed to sit inside the insert and, therefore, the PCR will show 
nothing if the insert is not present. 
Primer Name Sequence 
M13gV_5 GTC AGG GCA AGC CTT ATT CAC TG 
Psi_3 GCG TAA CGA TCT AAA GTT TTG TCG 
Thrombin_3 CGA ACC ACG CGG AAC CAG AC 
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5.2.8 Incorporation of Azidophenylalanine into Phage Libraries 
The TOP10-F’ cells transformed with the suppressor plasmid pAC-AzES-6TRN were 
streaked from a glycerol stock on an LB agar plate supplemented with ampicillin (100 µg/mL) and 
tetracycline (12.5 µg/mL). A single colony was inoculated into LB broth with appropriate 
antibiotics, and grown overnight at 37°C.  The starter culture was diluted 100-fold into 20mL of 
LB + 12.5 μg/mL Tet + 100 μg/mL Amp, and allowed to grow for two hours at 37°C to early log 
phase (OD600 = ~0.1).  A stock solution of azidophenylalanine was freshly prepared by dissolving 8 
mg of amino acid in 250 μL of DMSO and 250 μL of acidic water (pH = 2.0) The entire volume of 
the stock azidophenylalanine solution was added to the culture to achieve the final concentration 
of 2 mM.  For a control culture with no amino acid, only the 250 μL DMSO and 250 μL pH = 2.0 
water are added.  The cultures were then allowed to grow for additional one hour before the 
phage stock was added.  For the target screen hits, the entire 1.2 mL phage elution was added to 
the growing culture.  For the previously amplified library, phage amounts of 100 times the library 
diversity were added.  The phage culture was then allowed to grow for 5 hours, centrifuged at 
4500 rpm to remove the cells, and the top 80% of the supernatant was collected and precipitated 
with 1/6th volume of PEG/NaCl overnight at 4°C.  The mixture containing the precipitated phage 
was centrifuged at 14,000 rpm for 15 minutes. The pellet was dissolved in 200 μL TBS and spun 
down again at 14,000 rpm to remove cellular debris.  The total number of recovered phages was 
estimated before titering by measuring the absorbance at 
269 nm and 320 nm with a NanoDrop spectrophotometer 
and using the formula in Figure 5-9 from the Antibody 
Design Laboratories website8, where the vector size was set to 7200bp for M13KE.  
  
 
Figure 5-9: Formula for Estimation of Phage 
Concentration. 
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5.2.9 Optimized Phage Library Click Screening Conditions 
The click phage screens were performed on the library containing the azidophenylalanine 
after the incorporation step.  These screens were performed exactly as the target screen, except 
that the phage library was incubated with the target on resin overnight at room temperature to 




5.3 Results and Discussion 
5.3.1 Test of Azidophenylalanine Incorporation into a Protein in E.coli 
The first test was to determine whether, and if so, in which condition the suppressor 
plasmid pAC-AzPheRS-6TRN created by the series of mutagenesis described in 5.2.1 is effective in 
incorporating azidophenylalanine into a recombinant protein in E. coli in response to an amber 
codon.  Because the plasmid contains a chloramphenicol resistant marker (CmR) with an amber 
codon in its coding sequence (CAT-D112TAG), this antibiotic resistance is only conferred upon 
successful suppression of amber codon to synthesize the full-length protein.  When grown in the 
presence of chloramphenicol in a liquid medium, only the culture containing the 
 
Figure 5-10: Phage Click Screening Strategy.  a.) The phage library is precleared for TentaGel and sticky binders by 
preincubating the library with a scrambled epitope on resin.  b.)  The phage are then incubated with the target overnight 
for a click to form, washed extensively, and eluted from the resin by thrombin cleavage for amplification in e.coli or 
titering and sequencing. 
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azidophenylalanine amino acid was able to survive, as seen in Figure 5-11, with measured ODs of 
0.639 with added azidophenylalanine as opposed to 0.108 with control.  This result indicates that 
the mutated MjTyrRS for azidophenylalanine is functional and incorporating azidophenylalanine 
amino acid into the amber stop codon of the protein.  It also indicates that the conditions used 
for this incorporation are sufficient to keep the background 
suppression without the unnatural amino acid to a negligible 
level. 
 
5.3.2 Test of Azidophenylalanine Incorporation 
into M13KE Phage 
After the successful incorporation of the 
azidophenylalanine amino acid into a protein in E.coli, the 
incorporation was tested using a small number of M13KE phage 
clones that contain representative display peptide sequences 
similar to the library that was designed for the subsequent in situ click screening.  The 
azidophenylalanine incorporation was performed using four phage clones individually, and the 
presence of azide moiety in the collected phages was tested by clicking on an alkyne-containing 
TAMRA dye using a Click-It Kit (Invitrogen).  This allowed for the fluorescence visualization of the 
dye-labeled pIII protein resolved by SDS-PAGE.  As seen in Figure 5-12, there is one band across 
three of the four lanes corresponding to ~65kDa, or the running weight of the pIII phage coat 
protein, indicating that three of the four phage clones showed incorporation of the 
azidophenylalanine.  The fourth phage could have been incorporating improperly or could have 
been lost in the multiple steps of the experiment, since the quantities of phage used were very 
small.  Also, there are no other bands present in the gel which would indicate nonspecific azide 
incorporation in other proteins in the phage.  This suggests that the incorporation of 
 
Figure 5-11: Test of azide 
incorporation in e.coli. 
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azidophenylalanine is specific to the pIII protein where amber codon is introduced, and that 
peptides containing azidophenylalanine at a precise location can be displayed on the phage 
surface. 
 
5.3.3 Phage Library Screening Conditions 
and Results 
The original phage library produced by Antibody 
Design Labs contained about 35% naked phage 
determined by titering followed by plaque PCR, and 
cannot be directly carried onto the azidophenylalanine 
incorporation. The high prevalence of naked phage in 
the library complicates the subsequent 
azidophenylalanine incorporation, as the rapidly 
infecting naked phages that do not require suppression 
of the amber codon have a significant growth advantage 
over the properly-inserted phages, and can overwhelm the relatively slow synthesis of 
azidophenylalanine-containing phages by amber suppression.  For this reason, the traditional 
phage display screening methods–“target” screens searching only for binding of the library 
component to the target of interest–were used to minimize the number of naked phages present 
in the incorporation step.  The target screens eluted with thrombin cleavage were able to reduce 
the total amount of naked phage seen on titer plates to about 18%.  Unfortunately, when this 
pool of eluted target hits was amplified using a naturally-suppressing E. coli strain XL1-Blue, this 
number rose to 85%-too high to use for any incorporation.  An enrichment strategy that can 
reduce the number of naked phage to a manageable level has yet to be achieved. 
 
 
Figure 5-12: Click-It Kit Visualization of Azide in 
pIII Coat Protein.  The band seen above 
corresponds to ~65kDa, the known running 
mass of the pIII protein. 
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5.3.4 Focused Library Screening 
Because the amount of naked phages cannot 
be reduced to a level that would allow for successful 
azidophenylalanine incorporation, a “focused” 
library was designed from the insert-containing hit 
phages isolated from a target screen.  Figure 5-13 
shows a result from the plaque PCR that was 
completed after a target screen to search for phages 
containing inserts.  In this gel, each lane represents a 
single hit clone, and lanes 2, 4, and 6 show naked phages, as indicated by the PCR product of lower 
molecular weight.  The phage plaques that were tested in this PCR were also individually amplified 
in 1mL cultures in order to create a small pool of each sequence.  The 13 insert-containing plaques 
were then sequenced to ensure that each one contained an insert.  As can be seen in Table 5-4, 
only 11 of the 13 hits contained one clean sequence.  The rest appeared to have multiple 
sequences and may have had some naked phage contamination, and were thus eliminated from 
our pool of potential hits.  Therefore, out of this target screen, 11 of the amplified stocks that 
contained inserts (Table 5-4) were pooled to create a “focused” library of phage that are known 
to bind to the target.  This focused library has the added advantage of containing no naked phage, 
so it is the ideal library to be used to test the conditions for the azidophenylalanine incorporation.  
It will also be used for the subsequent focused library click screen with the target to test the in 





Figure 5-13: Gel Image of Colony PCR. This test for 
library insert shows only 3 naked phage, lanes 2, 4, 
and 6.  Out of 16 plaques total (not all shown on 
this gel), 13 contained an insert, and were used for 
the “focused” library. 
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Table 5-4: Hits from 13 Insert-Containing Phages, Figure 5-13 
#1 Amber D A L L P T V 
#3 Amber N S T Y A N S 
#4 Amber I S A Y L I Q 
#5 Uncallable, multiple sequence 
#6 Amber A F S A L D L 
#8 Amber M L V P L K P 
#10 Amber M D T W L M T 
#11 Amber T L M G Q W W 
#12 Amber S Y T T M E V 
#13 Amber G V G G P G P 
#14 Uncallable, multiple sequence 
#15 Amber E W W P G V W 




The difficulties associated with the original library itself have delayed the testing of the 
described technology, though a roundabout solution to that problem has been discovered.  The 
focused library is currently undergoing testing as the proof-of-concept for the click phage 
screening. 
Future libraries for azidophenylalanine incorporation should be built using a phage vector 
that is out of frame, so that the insert is required in order to correctly synthesize the pIII coat 
protein.  This will entirely eliminate the problem with the naked phage, and the complicated 
screening strategies will no longer be as important. 
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 Appendix A 
Use, Care and Maintenance of Procise 494 CLC 
Edman Degradation Protein Sequencer 
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A.1 Regular Use 
A.1.1 Loading a Bead 
 There are 4 cartridges on the Edman, and each can be loaded with a bead.  The cartridge 
is unscrewed from the machine, and the lid with the hose coming out of the top should ALWAYS 
be rested on the cartridge holder, and not left to dangle.  This stretches out that hose, and it will 
need to be replaced.  The cartridge top unscrews.  Inside, there are two quartz sample holders, 
and the bead fits in between them.  With gloves on, use a finger on each side of the cartridge to 
hold the second quartz sample holder in place while you turn the cartridge upside-down and let 
the top part slide out.  These quartz sample holders are VERY expensive, and chip easily.  Do not 
drop them, and be very careful when handling them.  Once the top sample holder is out, there 
should be a used filter and cartridge seal that can be removed and thrown out.  A new cartridge 
seal is slid into the cartridge on top of the bottom sample holder that was left in place.  A new 
filter gets tapped into the groove in the top sample holder that was removed.  It can be gently 
tapped in place with tweezers.  The bead is placed onto this filter, and the whole cartridge is then 
turned upside down, with the bottom sample holder and cartridge seal held in place by a finger 
on each side of the cartridge and slid down on top of the top sample holder that has the bead on 
top.  Then, the cartridge can be turned right-side-up, the lid can be screwed back on, and it can 
be placed back into its slot on the Edman. 
 The run is set up on the Procise software on the computer.  Each run should be set to use 
the “PulsedLiquid cLC” method, unless a special one is required.  The cycles should be set to equal 
the number of desired amino acids plus 3 – one warm-up cycle, one blank cycle and one standard 
cycle – that run automatically.  All of the solvent bottles should be checked to ensure that the 
levels are appropriate for running the desired amount of cycles.  You can check the amount of 
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each solvent required by clicking the button on the bottom of the screen.  It will provide an 
amount in mL required to run the set cartridges and cycles. 
 
A.1.2 Solvents 
 Most of the solvents used are purchased from somewhere other than Applied Biosystems, 
and mixed in house.  See  
Table A-1 for details.  When refilling solvents, the bottle should be screwed on until you hear three 
clicks.  Over-tightening can damage the assembly, such as the R1 bottle.  To loosen or tighten this 
bottle, you must first push up hard on the rachet assembly to hold it in place while you screw or 
unscrew the bottle. 
Table A-1: Solvent Compositions 
Letter Name Composition 
   
HPLC Solvents  
B2 Acetonitrile in Isopropanol 9:1 Acetonitrile:Isopropanol 
A3 THF in water 3.5% THF in water, 100uL stock Na2PO4, 1mL 
1% Acetone, 10mL Buffer premix, 20uL TFA 
   
Machine Solvents  
R1 PITC in Heptane 2.5mL PITC in 50mL heptane 
R2B N-methylpiperidine/MeOH/H2O  
R3 TFA, neat purchased from Sigma 
R4A 25% TFA in Water, DTT 12.5mL TFA in 37.5mL water with 0.01% DTT 
(32uL 1M stock) 
R5 Acetonitrile with 0.0001% DTT  
S1 N-heptane purchased from Sigma 
S2B Ethyl Acetate 450mL Ethyl Acetate with 225uL 1M DTT 
S3 N-Butyl Chloride purchased from Sigma 
S4B 20% Acetonitrile in water 20% Acetonitrile in water 
   
Stocks   
 Na2PO4 stock 2g in 15mL 3.5% THF in water 
 1M DTT stock 0.231g in 1.5mL Ethyl acetate or water 
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A.1.3 Ordering 
Table A-2: Parts and Chemicals Commonly Ordered from Applied Biosystems 
Part/Chemical Part Number 
Premix Buffer Concentrate, 100mL 401446 
R5B, Acetonitrile/n-Acetylcysteine, 40 mL 4340966 
Seal, Cylinder Head 200240 
Seal, 5mm Micro Pump 201399 
Procise Cartridge Seals (50/pk) 401611 
PTH-C18 Column, 0.8mm x 250mm 401882 
PTH Amino Acid Standards 4340968 




9mm TFA Filters 401111 
 
Table A-3: Parts and Chemicals Commonly Ordered from Sigma Aldrich 
Part/Chemical Part Number  
Ethyl Acetate CHROMASOLV® Plus, 99.9% 650528-4L 
Phenyl Isothiocyanate 78780 
Heptane, CHROMASOLV Plus, 99.9% 650536-4L 
2L Chromasolve N-Butyl Chloride for HPLC 34958-2L 
Trifluoroacetic Acid, 99% reagent plus T6508-1L 
 
A.1.4 Contacting AB 
 The number to call to place a service call with Applied Biosystems is (800) – 831 – 6844, 
press #4, then #1.  Our serial number is 4CL000092.  Ask for service on the instrument and get a 
reference number for the call.  Type this onto the purchase order, and have the purchasing 
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A.1.5 Idle machine 
 The machine should never be left completely idle, or the column can dry out and will need 
to be replaced.  If the machine is not running, press the “Manual” button on the front of the 
pumps.  It should turn the pumps on to 5uL/min at 50%B, and the bottom of that window will 




 These are our common settings for the machine in the off chance that something is lost 
or rest and needs to be reprogrammed.  These are also the settings used for all of the amino acid 




Table A-4: PulsedLiquid cLC Method 












Figure A-1: Temperature and Pressure Settings 






A.2.1 Computer Errors, Freezing, or Not Saving Spectra 
 The computer needs to be restarted frequently, more so when people use the computer 
for other uses.  Try to restart the computer once a week to prevent the loss of spectra, and keep 
people from using the computer for any other purpose, especially while the machine is running.  
If a computer error occurs, or the computer or sequencer freeze, shut down the computer and 
both the Procise machine and the pumps.  Turn them both back on, and they should sync up 
properly and continue running. 
 
Figure A-2: Normal1 cLC Gradient 
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A.2.2 Machine Bottle Runs Dry 
 When a bottle on the machine runs dry, air bubbles can get into the lines, and it will not 
be able to detect the solvent even after the bottle is refilled.  In order to fix this, the line will need 
to be backflushed.  After the solvent bottle has been refilled, go to the tab in the Procise software 
called “Manual Control” and find the solvent bottle that needs to be backflushed in either the 
“Flask Functions” tab or “Cartridge Functions” tab.  For example, in Figure A-3, the Flask Function 
“Backflush S3” is highlighted.  Once it is highlighted, click “execute” on the bottom of the screen, 
and watch the bottom of the hose in the solvent bottle until bubbles can be seen coming out.  
Then press “All Off” to shut off the backflush, and the solvent should now be detected.  The run 
can now be restarted. 
 
A.2.3 HPLC Bottle Runs Dry 
 Sometimes the HPLC solvent bottles run dry, and this is not as easily fixed as the machine 
bottles.  First, the HPLC bottles need to be refilled.  Then the pump must be purged manually 
using the buttons on the front of the pumps.  Push the function key for purge, then select the 
pump to be purged.  When the purge is complete, push “Manual” on the front of the pump to 
turn the pumps on to free running.  The pumps should be allowed to run freely until bubbles are 
no longer coming from the end of the column (as seen in the waste line).  If the machine is needed 
immediately, the flow rate can be turned up to move this process along faster. 
 Everything should be done to minimize the times that these bottles are allowed to run 
dry, so that the pumps are not pumping dry and the column does not dry out. 
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A.2.4 Baseline Errors – Dip at front of Spectra 
 A dip at the front of the spectra, as seen in Figure A-4, causing difficulty in reading the 
amino acid sequence, is a fairly common problem that indicates that the pump seals need to be 
changed.  In order to do this, you must unscrew the grey metal screw going into the pump 
cylinder, then unscrew the black ring around the top of the cylinder.  Remove the cylinder by using 
the purge function of the pumps to purge the pump you are working on, and PUSH the cylinder 
out.  NEVER PULL the cylinder out – it could damage the pumps, which are nearly impossible to 
replace on this machine.  Once the cylinder has been pushed out fully and starts getting pulled 
back in, push stop to keep it out.  Gently pull the cylinder off of the post.  One of the pump seals 
that needs to be changed is the one on the end of the post.  It is frequently hard to remove, and 
 
Figure A-3: Procise Screen for Backflushing a Line 
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can be sliced off or yanked with pliers.  The second pump seal is the ring inside of the metal part 
at the top of the cylinder – pull this off to expose the seal. 
 To put the cylinder back onto the post, do NOT just push.  If it is not aligned correctly, this 
can damage the inside of the cylinder, which cannot be replaced.  Use the metal alignment tool 
in the spare parts drawer.  This part has two pieces that come together to form a tunnel that fits 
onto the end of the cylinder, through which you can slide the cylinder post.  Before doing this, 
take a piece of Parafilm to cover the hole into the pump cylinder.  If one of the metal alignment 
pieces falls in, it will be VERY difficult to remove.  Then, while holding the metal pieces to the end 
of the cylinder, align this with the post, and apply steady but hard pressure to push the cylinder 
onto the post.  You will feel a click when it is on properly, and it will not pull back off if you tug on 
it.  Then, by tilting the cylinder back and forth, pull off the metal alignment pieces, then the 
Parafilm.  Use the purge function to pull this cylinder back down into the pump.  One that is in, it 
will need twisted so that it aligns properly and slides into place.  There is a notch it must fit into.  
Then, the black ring can be screwed back on, followed by the metal screw. 
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A.2.5 Baseline Errors – Stretched Out Amino Acid Standards 
 If the amino acid standards look very stretched out and are not completing by the end of 
the HPLC run, or if the DPTU peak is shifting from cycle to cycle, there is most likely a leak in the 
pumps.  This is a fairly easy fix, which requires looking at all of the screws around the pumps.  One 
of them will more than likely have a ring of salt around it.  Wash the salt off, and tighten the screw 
¼ turn.  It should fix the spectra problems immediately. 
A.2.6 Pressure Errors – Change Bottle Seals 
 Occasionally, when the machine has difficulty adding a solvent, it is due to a faulty rachet 
cap assembly, or the part that the bottle screws into on the machine.  In order to test this, go to 
the “Test Procedure” tab on the Procise software, and select “Leak” test.  Scroll down to the 
appropriate bottle, and try a leak test.  If it fails, but the bottle is screwed in tightly, this assembly 
should be replaced.  See page 9-19 in the User Manual for details on this procedure.  Once this 
 
Figure A-4: Dip at Front of Spectra Indicative of Bad Pump Seal 
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assembly has been replaced, the seal should no longer leak, and the solvent delivery should 




A.2.7 Pressure Errors – Clogged Lines 
 Overpressure errors on the Edman can sometimes be related to a clogged line.  Use the 
error message to try to find the line that might be clogged.  The line can either be replaced by 




Figure A-5: Leak Test Procise Software Screen 
